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Black Americans have an increased risk for developing a variety of cardiovascular 
disease (CVD) when compared to white Americans and other populations in the United 
States. It has also been demonstrated that the underlying impairments in black Americans 
manifest during early adulthood prior to any overt signs of risk, which leads to higher rates 
of CVD related morbidity and mortality in black Americans than other populations. 
Study 1 was designed to investigate the potential mechanisms of cutaneous 
microvascular dysfunction in young college-age black Americans. This was assessed by 
measuring the skin blood flow response to local heating while various vasoactive 
substances were delivered into the cutaneous interstitial space by intradermal 
microdialysis. We demonstrated that an attenuated nitric oxide (NO) mediated vasodilation 
due in part to a relative deficit of L-arginine in the endothelial cells is one mechanism by 
which microvascular dysfunction occurs in young black Americans. 
Study 2 conducted to investigate the effects of acute cocoa flavanol intake on 
cutaneous microvascular function in young black Americans. This was assessed by 
measuring the skin blood flow response to local heating and delivery of vasoactive 
substances (as described above) before and after consumption of a beverage high in 
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flavanol content. Study 2 demonstrated that acute flavanol intake improved cutaneous 
microvascular function in response to local heating in young black Americans relative to 
young white Americans.  
Study 3 was designed to investigate the effects of acute flavonal intake on 
endothelium-dependent microvascular dilation in response to exogenous administration of 
methacholine (MCh) in young black Americans. This was assessed by skin blood flow 
responses to incremental dose of MCh, which was delivered by intradermal microdialysis, 
before and after consumption of a beverage high in polyphenol content. Study 3 identified 
that acute flavanol intake did not alter the dose-response curve of MCh-induced cutaneous 
vasodilation in either racial groups. 
Overall, the series of studies in this dissertation may provide evidence that young 
black Americans have attenuated microvascular function relative to young white 
Americans, and that a potential mechanism of decreased microvascular function is a 
decrease in NO bioavailability and/or NO mediated vasodilation, which is related to a 
deficit of L-arginine in the endothelial cells in young black Americans. Furthermore, our 
findings may provide evidence that the consumption of cocoa flavanols is an effective 
therapeutic strategy to prevent and/or delay the development of CVD at least in young 
black Americans.  
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Chapter 1: Introduction 
Cardiovascular disease (CVD) is a class of disease, which includes hypertension, 
heart disease, stroke, and peripheral artery disease. Although overall mortality from CVD 
has continued to decrease over recent decades, CVD is still the leading cause of death in 
the United States. It is currently estimated that 83 million adults suffer from CVD. In 2008, 
the estimated annual direct and indirect costs associated with the treatment of CVD was 
already about 300 billion dollars [1]. Research supports the conclusion that ethnicity has 
an effect on the progression and the manifestation of CVD [2]. Interestingly, black 
Americans have an increased risk for developing a variety of CVD when compared to white 
Americans in the United States [3, 4]. It is also believed that underlying impairments in 
black Americans manifest in early adulthood prior to any overt signs of risk, which leads 
to higher rates of morbidity and mortality in black Americans than white Americans [5-7]. 
The mechanisms of elevated CVD risk in black Americans are multifactorial; 
however, there is abundant evidence showing that microvascular endothelial dysfunction 
is a major contributing factor. Endothelial cells maintain vascular tone and homeostasis 
through a variety of mediators ultimately resulting in a balance between vasorelaxation and 
vasoconstriction. Nitric oxide (NO) is a potent vasodilator which is released from 
endothelium. A decrease in NO bioavailability and/or a blood vessels ability to respond to 
NO and a decrease in vascular compliance cause the balance of vascular tone in the 
microcirculation to shift toward vasoconstrictive forces [8-10], causing microvascular 
dysfunction. Impaired microvascular function due to a decrease in NO bioavailability 
and/or a blood vessels ability to respond to NO is now considered a precursor to 
macrovascular dysfunction and is a major contributor to the development of CVD [11-13].  
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Diet is one of the modifiable lifestyle factors that plays a pivotal role in the primary 
and secondary prevention of CVD [14]. Flavonoids found in fruits and vegetables have 
received much attention because of their potential beneficial effects on cardiovascular 
health [15]. Epidemiological studies suggest that the beneficial effects of flavonoids on 
cardiovascular health are predominantly provided by flavanols, which is one of the 
subgroups of flavonoids [16-18]. The exact relationship between flavanol intake and 
cardiovascular health have not been fully identified. However, the findings from 
interventional studies suggest that the benefits of flavanol intake are linked to an 
improvement in endothelial function via an enhanced NO bioavailability and/or a blood 
vessels ability to respond to NO in healthy individuals as well as in populations with 
increased cardiovascular disease risk [19-22].  
Despite the well-known and unfortunate disparity between black Americans and 
white Americans regarding cardiovascular risk, less is known how microvascular 
dysfunction affects increased cardiovascular risk and how flavanol intake improves 
endothelial health in the microvasculature in black Americans. Therefore, this dissertation 
investigated the underlying mechanisms of microvascular dysfunction in young black 
Americans and the effects of flavanol intake on microvascular function as a preventive 




Chapter 2: Statement of the Problem 
 Cardiovascular disease (CVD) is the leading cause of deaths and the financial burden 
associated with the treatment of CVD are estimated to increase continuously in the 
United States as well as worldwide, which suggests the significance of developing ways 
to prevent and delay the initiation of CVD. 
 Black Americans are at a higher risk for developing a variety of CVD including 
hypertension, stroke, peripheral artery disease, and type 2 diabetes relative to white 
Americans [3, 4, 23]. 
 The underlying impairments which contribute to future disease risk in black Americans 
reveal in young adults prior to any overt signs of risk [5, 24]. 
 We have recently reported that cerebral vasodilatory capacity is blunted in college-aged 
black Americans relative to white Americans counterparts [25], suggesting endothelial 
dysfunction in young black Americans. Furthermore, we have also recently reported 
that impaired cerebral vasodilatory capacity in this population is reversed following 
acute consumption of a beverage that is high in flavanol content [26].  
 The findings from interventional studies have suggested that the benefits of flavanol 
intake are partially linked to improved endothelial function via enhanced nitric oxide 
(NO) bioavailability and/or a blood vessels ability to respond to NO in healthy 
individuals as well as in populations with elevated cardiovascular disease risk [19-22]. 
 
Study 1 of this dissertation was designed to investigate cutaneous microvascular 
function in healthy young black Americans in order to determine the potential mechanisms 
of microvascular dysfunction as they are associated with an increased risk for CVD. Study 
2 was designed to investigate the effects of acute cocoa flavanol consumption on 
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microvascular function in healthy young black Americans in order to determine whether 
the benefits of acute flavanol intake could be directly applied to restore attenuated 
microvascular function in young black Americans. Last, study 3 aimed to investigate the 
effects of flavanol intake on methacholine-induced NO-dependent microvascular function 
in healthy young black Americans in order to determine whether acute flavanol intake 





Chapter 3: Experimental Design 
To accomplish the aims of this dissertation, three studies utilizing local 
administration of vasoactive substances into the cutaneous microcirculation via the 
intradermal microdiaysis technique were conducted. The measurement of cutaneous 
microvascular function via this technique is advantageous because it is minimally invasive 
and allows for the manipulation of local skin blood flow in response to a variety of 
vasoactive substances that can stimulate or inhibit a variety of physiological pathways and 
its molecular reactions. Therefore, it provides a powerful tool to mechanistically assess 
microvascular function.   
The purpose of study 1 was to investigate cutaneous microvascular function in 
response to a typical local heating protocol in young black Americans in order to determine 
the potential mechanisms of microvascular dysfunction as they are associated with an 
increased risk for cardiovascular disease in this population. Healthy subjects conducted a 
typical local heating protocol. Cutaneous vascular conductance (CVC) was calculated as 
red blood cell (RBC) flux divided by mean arterial pressure (MAP) for an index of 
cutaneous microvascular function. All CVC data were presented as a percentage of the 
maximal CVC (%CVCmax) achieved during 43 °C local skin heating combined with local 
infusion of 28 mM sodium nitroprusside (SNP) which is an exogenous NO donor. We 
tested the hypothesis that CVC in response to local heating of skin would be attenuated in 
young black Americans relative to age-matched white Americans due to the lack of nitric 
oxide (NO) bioavailability and/or a blood vessels ability to respond to NO. Furthermore, 
we additionally tested the hypothesis that this reduced CVC in young black Americans 
would be restored with the intradermal infusion of L-arginine and arginase inhibitors, 
respectively. 
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The purpose of study 2 was to investigate the effects of acute cocoa flavanol intake 
on microvascular response to the aforementioned typical local heating of skin in young 
black Americans. A randomized, double-blind, and placebo-controlled cross-over design 
were conducted in this study. Based on the design, all subjects reported to the laboratory 
on two different days, separated by a minimum of 1 week, as the subjects consumed either 
a beverage high in flavanol content or a nutrient-matched placebo beverage with the 
exception that it contained no flavanols. CVC was calculated as RBC flux divided by MAP 
for an index of cutaneous microvascular function. All CVC data were presented as 
%CVCmax achieved during 43 °C local skin heating combined with local infusion of 28 
mM SNP. We tested the hypothesis that acute flavanol intake would improve CVC in 
response to local heating of skin in the black American group while there is less of or no 
improvements of CVC with acute flavanol intake in the white American group. 
The purpose of study 3 was to investigate the effects of acute flavonal intake on 
NO-dependent microvascular dilation in response to exogenous administration of 
incremental doses of methacholine (MCh) in young black Americans. A randomized, 
double-blind, and placebo-controlled cross-over design were conducted in this study. 
Based on the design, all subjects reported to the laboratory on two different days, separated 
by a minimum of 1 weak, as the subjects consumed either a beverage high in flavanol 
content or a nutrient-matched placebo beverage with the exception that it contained no 
flavanols. CVC was calculated as RBC flux divided by MAP for an index of cutaneous 
microvascular function. All CVC data were presented as %CVCmax achieved during 43 
°C local skin heating combined with local infusion of 28 mM SNP. We tested the 
hypothesis that the EC50, i.e. the concentration of MCh required to elicit 50% of the 
maximal response, would be higher in the black Americans (indicative of vascular 
dysfunction). Additionally, we also tested the hypothesis that the consumption of flavanol-
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containing beverage would produce a leftward shift in the dose-response curve of MCh-
induced cutaneous vasodilation in young black Americans, while there would be no effects 
of acute flavanol intake in young white Americans. 
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Chapter 4: Study One 
  
The Effects of Nitric Oxide Bioavailability on Cutaneous Microvascular Function in 




Black Americans are at an increased risk for developing a variety of cardiovascular 
disease relative to white Americans and other populations. Underlying impairments 
manifest early in young adults prior to overt signs of risk. The mechanisms of this increased 
risk are multifactorial; however, recent evidence suggests that microvascular dysfunction 
in young black Americans is a primary contributor. This study tested the hypothesis that 
microvascular function, indexed by the cutaneous vascular conductance (CVC), in 
response to local heating of skin would be attenuated in young black Americans relative to 
age-matched white Americans due to the lack of nitric oxide (NO) bioavailability and/or 
an impaired vasodilatory response to NO. Furthermore, we additionally tested the 
hypothesis that this reduced CVC in young black Americans would be restored following 
intradermal infusion of L-arginine and an inhibitor of arginase, respectively. 
Nine black Americans and nine white Americans adults participated in this study. 
Four microdialysis membranes were placed in each subject’s non-dominant forearm. Each 
microdialysis site was randomly assigned to receive 1) lactated Ringer’s solution as a 
control, 2) 20 mM NG-nitro-L-arginine (L-NAME) to inhibit NO, 3) 10 mM L-Arginine 
to locally supplement the substrate for NO synthase, or 4) a combination of 5.0 mM (S)-
(2-boronoethyl)-L-cysteine-HCL (BEC) and 5.0 mM Nω -hydroxy-nor-L-arginine (nor-
NOHA) to locally inhibit arginase activity at a rate of 2 μl/min. Skin blood flow (SkBF) 
was assessed while the skin was clamped at 33 °C for 10 min followed by 42 °C for ~ 30 
min and values were normalized to a maximal value obtained during 43 °C local heating 
combined with infusion of 28 mM of sodium nitroprusside (SNP). CVC was calculated as 
SkBF/mean arterial pressure and normalized as a percentage of maximal CVC 
(%CVCmax). The difference in %CVCmax between the control site and L-NAME site 
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across the rise in skin temperature was calculated to assess the NO contribution (Δ 
%CVCmax). 
There was no difference in the baseline %CVCmax at 33 °C between groups at all 
sites (all P > 0.05). At 42 °C, the plateau %CVCmax was significantly lower in the black 
American (BA) group than the white American (WA) group at the control site (BA: 62 ± 
6 vs. WA: 84 ± 12 %CVCmax; P < 0.001). In the BA group the plateau %CVCmax at 42 
°C was significantly elevated at the L-arginine supplemented site compare with the control 
site (Control: 62 ± 3 vs. L-arginine: 70 ± 3 %CVCmax; P = 0.048) but not at the arginase 
inhibited site (Control: 62 ± 3 vs. Arginase inhibitors: 62 ± 3 %CVCmax; P = 0.908). There 
was no change in the plateau %CVCmax following L-arginine supplemention (Control: 84 
± 3 vs. L-arginine: 83 ± 3 %CVCmax; P = 0.900) or arginase inhibition (Control: 84 ± 3 
vs. Arginase inhibitors: 81 ± 3 %CVCmax; P = 0.555) in the WA group. In addition, the 
BA group had an attenuated contribution of NO to cutaneous hyperemic response to the 
local heating relative to the WA group (BA: 44 ± 3 vs. WA: 53 ± 3 Δ %CVCmax; P < 
0.001) with a significant interaction between group and skin temperature (P = 0.018).  
Based on these findings we suggest that 1) cutaneous microvascular function in 
response to local heating of skin is blunted in young black Americans when compared to 
age-matched young white Americans; 2) this attenuated response is partly related to 
decrease in NO bioavailability in young black Americans; 3) a local infusion of L-arginine, 
but not arginase inhibition, improves cutaneous microvascular function in response to local 




Cardiovascular disease (CVD) is the number one cause of death in the United States 
[1]. Black Americans are known to be at increased risk for developing a wide variety of 
cardiovascular diseases including coronary artery disease, stroke, hypertension, and 
metabolic syndrome compared with white Americans [3, 4, 23, 27]. In addition, the 
underlying impairments resulting in these disease states manifest during early adulthood 
prior to any overt signs of risk in this population [5-7]. The mechanisms resulting in 
increased risk in this population are likely multifactorial; however, recent evidence 
suggests that endothelial dysfunction is a major contributing factor [23, 27]. Previous 
studies have demonstrated that the vascular dilatory capacity of resistance vessels is 
reduced in young black Americans relative to white Americans. For example, vasodilatory 
capacity of the forearm resistance vessels was attenuated in normotensive young black 
American men when compared to normotensive young white American men [28]. 
Similarly, forearm vasodilatory response to isoproterenol infusion, which is a β-adrenergic 
agonist, was blunted in normotensive young black American men relative to white 
American men [29]. Nitric oxide (NO)-mediated forearm blood flow responses to 
methacholine and sodium nitroprusside (SNP) administration were attenuated in healthy 
young black American men when compared to white American men [30]. These results 
suggest early onset of vascular dysfunction in young black Americans prior to any overt 
signs of risk compared with young white Americans.  
One potential mechanism that has been implicated in attenuated endothelial 
function in young black Americans is a decrease in NO bioavailability. NO is formed in 
the endothelial cells by the reaction of endothelial NO synthase (eNOS), which divide the 
substrate L-arginine into NO and L-citrulline, and acts as a primary vasoactive substance 
that plays a critical role in vasodilation [31]. The exact mechanisms of a decreased NO 
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bioavailability have not been fully elucidated. However, several potential signaling 
pathways of a decreased NO bioavailability, including eNOS uncoupling or deregulated 
utilization of the substrate L-arginine, have been suggested. It has recently shown that a 
low concentration of L-arginine can negatively effect on the production of NO in animals 
[32] and human cells [33], indicating that a decreased NO bioavailability due to eNOS 
uncoupling, may be related to a decreased concentrations of L-arginine [34].  
Arginase constitutively exists in two isoforms (arginase I and arginase II) in human 
cells. Both arginase isoforms convert L-arginine into L-ornithine and urea during the final 
step in the urea cycle [35]. In terms of vascular function, arginase I is predominant in the 
vasculature and is co-expressed with eNOS by sharing for the substrate L-arginine [36, 37]. 
Therefore, the overexpression or the increase in activity of arginase can affect eNOS 
coupling and NO bioavailability secondary to competition between eNOS and arginase for 
L-argnine [34, 38-40]. Several studies using animal models have implicated that an 
increased arginase activity could impair microvascular function due to decreased NO 
bioavailability, and this attenuated microvascular function could be restored with both 
acute and chronic inhibition of arginase activity [36, 37, 41]. 
The human cutaneous circulation serves as a surrogate vascular bed for the 
assessment of systemic microvascular dysfunction. It has been reported that impaired 
cutaneous microvascular reactivity is observed before any clinical signs of microvascular 
dysfunction during the early stages of diseases [42], suggesting the correlation between 
skin vascular reactivity and a systemic microvascular dysfunction. For this reason, skin 
blood flow (SkBF) response to local heating has been widely used as a means to examine 
microvascular dysfunction because of its ease of accessibility and non-invasive 
characteristics [42-46]. Additionally, the combination of laser-Doppler flowmetry (LDF) 
and intradermal microdialysis has been successfully used in skin reactivity tests to measure 
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microvascular function and determine the underlying mechanisms of microvascular 
dysfunction in both healthy individuals and individuals with elevated CVD risk factors 
including smoking [47], hypercholesterolemia [48], and hypertension [49]. 
To our knowledge, the racial difference in the functional roles of L-arginine and 
arginase in eNOS uncoupling and its potential contribution to a reduced NO-dependent 
vasodilation are unknown. Thus, the primary aim of this study was to test the hypothesis 
that microvascular function in response to local heating of skin would be attenuated in 
young black Americans relative to age-matched white Americans due largely to the lack 
of NO bioavailability. A secondary aim of this study was to test the hypothesis that an 
attenuated cutaneous microvascular function in young black Americans would be restored 




Ethical Approval and Subjects 
Eighteen young, healthy subjects (9 black Americans and 9 white Americans) 
volunteered for this study (Table 1.1). All subjects self-defined as black Americans or 
white Americans and were only accepted into the study if both parents were black 
Americans or white Americans, respectively. Before admission, all experimental 
procedures were explained to subjects and they were given an opportunity to ask questions. 
Subjects of each group gave written consent approved by the Institutional Research Board 
at the University of Texas at Austin and completed a questionnaire on medical history, 
medications, and lifestyle behaviors. All individuals were normally active with no history 
of cardiovascular, metabolic, or neurological disease. In addition, those currently taking 
any medication known to alter cardiovascular function were excluded. Given that smoking 
can affect the peripheral vascular response, individuals who are currently smokers or quit 
smoking within the prior two years were excluded [50]. All female subjects were only 
studied during the early follicular phase (within 1-3 days of the start of menstruation) to 
minimize the effects of female sex hormones [51, 52]. 
 
Instrumentation and Measurements 
On each study visit all subjects reported to the laboratory in the morning in the 
fasted condition (~12 hr), having refrained from strenuous exercise, alcohol, and caffeine 
for 24 hr. On the experimental day, height and weight of subjects was assessed (Seca 763, 
Seca, Chino, CA). Subjects were then asked to lie down on a patient bed in the semi-supine 
position for the remainder of data collection. Subjects were then instrumented with five 
electrodes for the assessment of cardiac rhythms and heart rate (HR) measured via an 
electrocardiogram (HP Patient Monitor, Agilent, Santa Clara, CA) interfaced with a 
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cardiotachometer (CWE, Ardmore, PA), and a blood pressure cuff on an upper arm for the 
assessment of arterial blood pressure measured from auscultation of the brachial artery via 
electrosphygmomanometry (Tango+; SunTech, Raleigh, NC). Following a minimum of 20 
min of rest, baseline HR and blood pressure were obtained in all subjects. Mean arterial 
pressure (MAP) was calculated as one-third pulse pressure plus diastolic blood pressure 
(DBP). 
Four intradermal microdialysis membranes (CMA 31 Linear Microdialysis Probe, 
55 kDa cut-off membrane; CMA Microdialysis AB, Holliston, MA) were instrumented on 
the ventral surface of the non-dominant forearm. For each membrane, a 25-gauge needle 
guide was inserted horizontally into the dermal layer of the skin such that entry and exit 
points on each site were ≥ 2.5 cm apart. The microdialysis membrane was threaded through 
the needle, which was then followed by withdrawal of the needle from the skin leaving the 
membrane in place. After all microdialysis membranes were inserted and taped in place, 
each site was continuously perfused with lactated Ringer’s solution at 2 μl/min via an 
infusion pump (Pump 11, Harvard Appartus, Natick, MA) for a 60-90 min to allow for 
local hyperemia associated with the needle insertion to subside [9, 53-58]. Skin blood flow 
(SkBF) was indexed over each microdialysis site using a LDF probe (VP7 A/T with 
moorVMS-LDF2; Moor Instruments, Wilmington, DE) which was housed in the center of 
a local heating element (PeriFlux System 5000; Perimed, Sweden). 
 
Experimental Protocol  
Following instrumentation and cessation of the hyperemia response (~90 min), the 
local heating elements were clamped at 33 ºC (i.e. thermoneutral skin temperature) for a 
15-min baseline data collection with each site receiving lactated ringers (2 μl/min). 
Following baseline data collection each experimental site was infused with its respective 
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vasoactive agents at a rate of 2 μl/min. All vasoactive substances were mixed and prepared 
just before use. Each microdialysis site was randomly assigned to receive: 1) lactated 
Ringer’s solution as a control site; 2) 20 mM NG-nitro-L-arginine (L-NAME); 3) 10 mM 
L-Arginine; or 4) a combination of 5.0 mM (S)-(2-boronoethyl)-L-cysteine-HCL (BEC) 
and 5.0 mM Nω -hydroxy-nor-L-arginine (nor-NOHA) at a rate of 2.0 μl/min. The 
concentrations of L-arginine and arginase inhibitors were decided to maximize cutaneous 
vasodilatory responses as the minimum dose based on previous study [34]. Following an 
additional 30 min baseline period the temperature of the local heaters was increased to 42 
ºC at a rate of 0.5 ºC every 5 sec and clamped at 42 ºC until a stable plateau was reached 
(approximately 30 min) (19) while each site continues to receive its respective vasoactive 
agent. Following this 30 min period, local temperature was increased to 43 ºC and each site 
was perfused 28 mM SNP (Sigma-Aldrich, St. Louis, MO) to induce maximal vasodilation 
[59]. This procedure induces a maximal SkBF response in the cutaneous circulation that is 
primarily NO dependent [56, 60-62]. Immediately following this period the local heating 
elements were turned off.  
 
Data Analysis  
Data were sampled at 125 Hz via a data-acquisition system (Biopac System, Santa 
Barbara, CA). Data from the last min of each local heating phase (i.e. 33, 42, and 43 °C) 
were averaged and used for analysis. Cutaneous vascular conductance (CVC) was 
calculated from the ratio of RBC flux to MAP. CVC was presented as a percent of each 
respective maximal SkBF achieved during 43 °C heating plus 28 mM SNP infusion 
(%CVCmax). The difference in %CVCmax between the control site and L-NAME site (Δ 
%CVCmax) across the rise in skin temperature was calculated to assess the NO 
contribution as an index of NO bioavailability.  
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Statistical Analysis 
All data were analyzed using a statistical software package (Stata 13; StataCorp LP, 
College Station, TX). Unpaired Student’s t-tests were performed to detect significant 
differences between the black American and white Americans group for physical 
characteristics and resting hemodynamic variables. A two-way repeated measure mixed 
model was conducted to estimate 1) the effects of group and drug site on absolute maximal 
CVC, 2) the effects of group and skin temperature on %CVCmax at the control site, and 
3) the effect of group and skin temperature on the NO contribution to vasodilation. A three-
way repeated measure mixed model was conducted to estimate the effects of group and 
drug sites (control vs. drug) on %CVCmax over the rise in skin temperature. Bonferroni 
correction were performed for post-hot analysis when a significant interaction was 
identified. All data were presented as means ± SE unless otherwise stated. The level of 




Subject Characteristics  
The physical characteristics of subjects are presented in Table 4.1. Subjects were 
well matched for age, height, weight, and body mass index (BMI) (all P > 0.05). There was 
no significant difference between groups for resting systolic blood pressure (SBP), 
diastolic blood pressure (DBP), MAP, and resting HR at the end of the insertion trauma 
resolution period (all P > 0.05). 
 
Microvascular Function 
Absolute maximal CVC. Table 4.2 shows absolute maximal CVC during combined 
43 °C local heating and 28 mM SNP infusion. Absolute maximal CVC was similar between 
groups across all sites (P > 0.05), demonstrating that the maximal vasodiatory capacity of 
the cutaneous microvasculature was similar between groups. There was no interaction 
between group and each treatment site relative to the control site (all P > 0.05) with no 
main effect of group and drug site (all P > 0.05). 
%CVCmax at the control site. Figure 4.1 shows a SkBF tracing from a 
representative subject in each group. Figure 4.2 summarizes the SkBF response during the 
local heating protocol in the control site in both groups. There was no difference in baseline 
%CVCmax during 33 °C local heating between the black American (BA) group and white 
American (WA) group in the control site (BA: 9 ± 3 vs. WA: 11 ± 3 %CVCmax; P = 
0.456). The plateau %CVCmax during 42 °C local heating was significantly lower in black 
Americans (BA: 62 ± 3 vs. WA: 84 ± 3 %CVCmax; P < 0.001). There was an interaction 
between group and skin temperature (P < 0.001) with a main effect of skin temperature (P 
< 0.001) and group (P < 0.001). 
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NOS inhibited site. Figure 4.3A summarizes the SkBF response during the local 
heating protocolin the NOS inhibited site in both groups. In the WA group, the baseline 
%CVCmax at 33 °C was similar compared with the control site (Control: 11± 3 vs. L-
NAME: 7 ± 3 %CVCmax; P = 0.326). The plateau %CVCmax at 42 °C was significantly 
different between the control and NOS-inhibited sites (Control: 84 ± 3 vs. L-NAME: 28 ± 
3 %CVCmax; P < 0.001). In the BA group, the baseline %CVCmax at 33 °C was similar 
compared with the control site (Control: 9 ± 3 vs. L-NAME: 4 ± 3 %CVCmax; P = 0.289). 
The plateau %CVCmax at 42 °C was significantly different between the control and NOS-
inhibited sites (Control: 62 ± 2 vs. L-NAME: 19 ± 2 %CVCmax; P < 0.001). There was 
no difference in baseline %CVCmax between groups in L-NAME site (P = 0.494). During 
42 °C local heating, there was a group difference in L-NAME site (P = 0.031). No 
significant interaction between group and drug site over a rise in local temperature was 
observed (P = 0.134). A significant three-way interaction was observed (group, local 
temperature, and drug site) (P = 0.044). There was a significant interaction between group 
and local temperature (P < 0.001) and between drug site and local temperature (P < 0.001) 
but not between group and drug site (P = 0.056). These significant interactions remained 
following Bonferroni correction. There was a significant main effect of local temperature, 
group, and drug site (all P < 0.001). 
L-arginine supplemented site. Figure 4.3B summarizes the SkBF response during 
the local heating protocol in the L-arginine supplemented site in both groups. Baseline 
%CVCmax during 33 °C local heating was similar between the control and the L-arginine 
sites in the WA group (Control: 11 ± 3 vs. L-arginine: 15 ± 3 %CVCmax; P = 0.414) and 
in the BA group (Control: 9 ± 3 vs. L-arginine: 10 ± 3 %CVCmax; P = 0.671). No group 
difference in the baseline %CVCmax was observed in L-arginine supplemented site (P = 
0.298). In the BA group, L-arginine supplementation increased the plateau %CVCmax at 
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42 °C when compare to the control site (Control: 62 ± 3 vs. L-arginine: 70 ± 3 %CVCmax; 
P = 0.048), while there was no effect in the WA group during 42 °C local heating with L-
arginine supplementation (Control: 84 ± 3 vs. L-arginine: 83 ± 3 %CVCmax; P = 0.900). 
During 42 °C, there was a group difference in the plateau %CVCmax observed in L-
arginine site (P < 0.001). There was a significant interaction between group and local 
temperature (P = 0.002) but not between drug site and local temperature (P = 0.801) or 
between group and drug site (P = 0.440). The significant interaction between group and 
local temperature remained following Bonferroni correction. There was a significant main 
effect of group (P < 0.001) and local temperature (P < 0.001) but not drug site (P = 0.143). 
Arginase inhibited site. Figure 4.3C summarizes the SkBF response during the local 
heating protocol in the arginase-inhibited site in both groups. In the WA group, there was 
no difference between the control and arginase-inhibited sites in baseline %CVCmax 
during 33 °C local heating (Control: 11 ± 3 vs. Arginase inhibitors: 14 ± 3 %CVCmax; P 
= 0.483) and in the plateau %CVCmax at 42 °C (Control: 84 ± 3 vs. Arginase inhibitors: 
81 ± 3 %CVCmax; P = 0.555). Similarly, in the BA group, there was no difference between 
the control and arginase-inhibited sites in the baseline %CVCmax at 33 °C (Control: 9 ± 3 
vs. Arginase inhibitors: 8 ± 3 %CVCmax; P = 0.876) and in the plateau %CVCmax at 42 
°C (Control: 62 ± 3 vs. Arginase inhibitors: 62 ± 3 %CVCmax; P = 0.908). No group 
difference in baseline %CVCmax was observed in the arginase-inhibited site (P = 0.153). 
During 42 °C local heating, a group difference in %CVCmax observed in the arginase 
inhibited site (P < 0.001). No significant three-way interaction was observed (P = 0.426). 
There was a significant interaction between group and local temperature (P < 0.001) but 
not between drug site and local temperature (P = 0.604) or between group and drug site (P 
= 0.939). The significant interaction between group and local temperature remained 
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following Bonferroni correction. There was a significant main effect of group (P < 0.001) 
and local temperature (P < 0.001) but not drug site (P = 0.972). 
NO contribution. Figure 4.4 shows the NO contribution during local heating in both 
groups. There was no difference in the baseline NO contribution at 33 °C between groups 
(BA: 4 ± 3 vs. WA: 4 ± 3 %CVCmax; P = 0.963). NO contribution at 42 °C was 
significantly lower in the BA group than the WA group (BA: 44 ± 3 vs. WA: 53 ± 3 
%CVCmax; P < 0.001). There was a significant interaction between group and local 
temperature (P < 0.001) with a significant main effect of local temperature (P < 0.001) and 
group (P < 0.001). The significant interaction between group and local temperature was 
remained with Bonferroni correction. 
%CVCmax at the plateau. Figure 4.5 displays mean %CVCmax for the plateau 
phase at 42 °C heating of skin in all sites. The plateau %CVCmax at 42 °C heating was a 
significantly lower in the BA group when compare to the WA group in the control site 
(BA: 62 ± 4 vs. WA: 84 ± 4 %CVCmax; P < 0.001), in the L-arginine supplemented site 
(BA: 70 ± 4 vs. white Americans: 83 ± 4 %CVCmax; P < 0.001), and in the arginase-
inhibited site (BA: 62 ± 4 vs. WA: 81 ± 4 %CVCmax; P < 0.001), while NOS inhibition 
significantly attenuated the plateau %CVCmax compare with the control site in the WA 
group (Control: 84 ± 4 vs. L-NAME: 28 ± 4 %CVCmax; P < 0.001) and the BA group 







The primary findings of this study are as following: 1) cutaneous vasodilation in 
response to local heating was blunted in young black Americans when compared to age-
matched young white Americans, 2) this attenuated response was related to decrease in NO 
bioavailability in young black Americans, and 3) a local administration of L-arginine 
improved cutaneous microvascular vasodilation during local heating in black Americans 
but not in white Americans; however, contrary to our initial hypothesis, local inhibition of 
arginase administration had no effect on cutaneous microvascular function in either group. 
These findings suggest that an attenuated NO bioavailability due partly to a relative deficit 
of L-arginine in the endothelial cells is one of the mechanisms by which microvascular 
dysfunction occurs in young black Americans. 
In the present study, %CVCmax was attenuated in response to 42 °C local heating 
in the BA group relative to the WA group while there was no different %CVCmax at 33 
°C and absolute CVC at 43 °C + SNP infusion. This indicates that there was no difference 
in baseline vasodilatory function and that both young black Americans and white 
Americans achieved similar maximal vasodilatoy response to 43 °C local heating plus SNP 
infusion. As hypothesized, the hyperemic response in the cutaneous microvasculature 
following 42 °C heating in young black Americans was significantly blunted relative to 
young white Americans. The findings in the current study support our recent finding that 
college-aged black Americans (23 years) have reduced cerebral vasodilatory capacity 
during rebreathing-induced hypercapnia relative to age-matched white Americans [25]. 
These findings are also consistent with previous studies of endothelial function of conduit 
artery in young black Americans. Forearm blood flow responses to exercise [28], ischemia 
[63], and mental stress [64] were significantly lower in healthy black Americans when 
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compare to healthy white Americans. Thus, our findings further support that microvascular 
function is impaired partly in young, healthy black Americans. 
NO bioavailability can be dictated based on the balance between the synthesis and 
degradation of NO in the vasculature, and we also found that NO contribution to local 
heating of skin was lower in young black Americans than white Americans in this study, 
suggesting a decreased NO bioavailability in young black Americans. Additionally, we 
found that attenuated microvascular function in young black Americans improved by the 
local administration of L-arginine in the current study. Studies have shown that a low 
concentration of L-arginine can limit the production of NO in both animals [32] and human 
cells [33], indicating that a decrease in the amount of L-arginine may reduce NO 
bioavailability. Thus, our finding suggests that the concentrations of available NO for 
eNOS in the endothelial cells and NO-dependent vasodilation is not enough to elicit the 
maximal SkBF response during local heating in young black Americans. 
In addition to L-arginine deficiency, it is possible that an increase in oxidative stress 
in young black Americans may cause to attenuated NO-dependent vasodilation. It is well 
known that upregulated superoxide (O2
−) reacts with NO and form peroxynitrite (ONOO−) 
faster than superoxide metabolism by superoxide dismutase [65], resulting in a decrease in 
NO bioavailability. It is evident that single human umbilical vein endothelial cell 
(HUVEC) isolated from young black American individuals (22 years) have reduced release 
of NO and increased production of both O2
− and ONOO− compared with age-matched 
white American individuals. In the same study, it has demonstrated that the expression of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase upregulated in HUVECs 
from young black American individuals relative to young white American individuals [66]. 
These findings suggest that an increased oxidative stress in young black Americans leads 
to decrease in NO bioavailability. 
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Alternatively, it is possible that tetrahydrobiopterin (BH4), the essential cofactor for 
the generation of NO by eNOS expression/activity may be attenuated in young black 
Americans. One possible mechanism of eNOS uncoupling related to BH4 has suggested 
that the formation of ONOO– due to elevated oxidation may oxidize BH4 [67]. Excessively 
produced O2
− by NADPH oxidase and/or xanthine oxidase (XO) can also bind with NO 
and form ONOO–. The oxidization of BH4 by ONOO
– is converted to BH3 or BH2 which 
are inactive forms of BH4, leading to eNOS uncoupling [68-70]. Furthermore, it has been 
assumed that ONOO– might oxidize the zinc-thiolate cluster of eNOS and destabilize 
eNOS dimer so eNOS is uncoupled [71]. Thus, it is plausible that the intradermal 
administration of L-arginine may lead to a synergistic response to local heating so that an 
increase in expression/activity of BH4, can contribute to increase in NO production and 
bioavailability in young black Americans. 
L-arginine in human cells not only binds with eNOS, but also with arginase [34, 
35, 38-40]. Arginase metabolizes L-arginine to L-ornithine and urea during the urea cycle 
and lead to reduce NO production by shunting the substrate from the eNOS pathway to the 
arginase pathway competing with eNOS for the substrate, L-arginine [72]. Thus, there is 
the possibility that upregulation of arginase may shunt the substrate L-arginine from eNOS 
pathway to arginase pathway, resulting in a decrease in NO bioavailability. Several studies 
has shown that arginase is upregulated in individuals with a variety diseased conditions 
including atherosclerosis [73], myocardial ischemia [74], and hypertension [75]. Contrary 
to these findings, the administration of arginase inhibitors did not affect the cutaneous 
microvascular response to local heating in young black Americans in the current study. 
Similarly, Holowatz et al. (2006) previously reported that intradermal administration of 
arginase inhibitors did not alter cutaneous vasodilation in young subjects [34]. The reasons 
for this remain unclear. It is plausible that the expression and/or activity of arginine may 
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be already low in young black Americans; thus, exogenous administration of arginase 
inhibitors did have no effects on NO bioavailability. It is also possible that the 
concentrations of arginase inhibitors used in the current study may be not enough to elicit 
maximal vasodilation. However, the concentrations of arginase inhibitors (5.0 mM BEC 
and 5.0 mM nor-NOHA) used in the current study have shown to be effective young and 
aged [34], and hypercholesterolaemic humans [48] using the same intradermal 
microdialysis technique and far exceed the Ki for the enzyme isoforms (BEC Ki at pH 7.5 
= 0.31 μm; nor-NOHA Ki at pH 7.5 = 1.6 μm) [76]. 
In the present study, the young white American group did not show any changes in 
cutaneous microvascular function with L-arginine supplementation and arginase 
inhibition. Additional studies are needed to confirm this results. However, it is likely that 
young and healthy white Americans individuals have low oxidative stress, low arginase 
activity, or high levels of L-arginine in the endothelial cells, which are responsible for the 
minimal or no changes in microvascular function. Taken together, these findings suggest 
that an attenuated NO bioavailability may related to the deficit of L-arginine concentrations 
in the endothelial cells and may be one of the mechanisms by which microvascular 




A limitation of the present study is that we did not co-infuse L-arginine and arginase 
inhibitors because of limited equipment to assess RBC flux at four sites. Thus, we are not 
able to clarify what their combined effect would be. In addition L-NAME was not co-
infused within L-arginine or arginase inhibition sites; thus we cannot determine whether 
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the improvement at the L-arginine supplemented site is dependent on NO bioavailability 
or not. 
Another limitation of the present study is the use of LDF to determine cutaneous 
microvascular function. Although the assessment of RBC flux using LDF has been widely 
used in studies for microvascular function, some technical challenges including inherent 
variability in LDF cannot be ruled out for the precise evaluation [77]. In the present study, 
we observed attenuated microvascular vasodilatory response in response to local heating 
of skin in young black Americans relative to age-matched white Americans; however, 
additional studies with other techniques are needed to be conducted to confirm our findings 
because the use of %CVCmax, calculated by LDF and MAP, provides only a relative index 
of SkBF response to local heating of skin.    
 
Conclusion 
In conclusion, this study demonstrated that young black Americans have attenuated 
microvascular function in response to a typical local heating protocol relative to the age-
matched white Americans. Furthermore, this data suggests that attenuated vasodilation is 
related to a decrease in NO bioavailability due to limited L-arginine availability in young 
black Americans. Considering attenuated NO-dependent vasodilation in young black 
Americans and the observed restoration of cutaneous microvascular function with the 
administration of L-arginine, exogenous L-arginine supplementation might be a novel 
potential therapeutic target to prevent racial disparities in cardiovascular disease. 
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4.6 TABLES AND FIGURES 
 
Table 4.1 Subject characteristics and resting hemodynamic variables  
N, no. of subjects; M, male; F, female; BMI, body mass index; HR, heart rate; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. Values are 











Characteristics    
Age (years) 24 ± 3 23 ± 3 0.33 
Sex (M/F) 6/3 6/3 1.00 
Height (cm) 173 ± 10 171 ± 10 0.79 
Weight (kg) 66 ± 10 68 ± 10 0.80 
BMI (kg/m2) 22 ± 1 23 ± 2 0.35 
Hemodynamics    
HR (beats/min) 57 ± 14 58 ± 7 0.82 
SBP (mmHg) 113 ± 9 116 ± 7 0.43 
DBP (mmHg) 70 ± 7 73 ± 9 0.46 





Table 4.2 Absolute maximal cutaneous vascular conductance (CVC) across all sites  
L-NAME, NG-nitro-L-arginine; arginase inhibitors, a combination of (S)-(2-boronoethyl)-
L-cysteine-HCL (BEC) and 5.0 mM Nω -hydroxy-nor-L-arginine (nor-NOHA). Absolute 
maximal CVC was similar between groups across all sites (all P > 0.05). Values are means 




 White American Black Americans 
Control 3.89 ± 0.27 3.19 ± 0.27 
L-NAME 3.50 ± 0.27 3.29 ± 0.27 
L-arginine 3.65 ± 0.27 3.08 ± 0.27 





Figure 4.1 Schematic representation of the skin blood flow (SkBF) response to local 
heating  
LDF, laser-Doppler flowmetry. A, initial peak; B, plateau; C, maxial SkBF induced by 
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Figure 4.2 A summary of cutaneous vascular conductance as a percentage of maximal 
vasodilation (%CVCmax) in response to local heating between groups at the ringer’s site 
(control)  
Open bars, white American (WA) group; Filled bars, black American (BA) group. 
%CVCmax during the rise in local temperature (°C) was lower in the BA group than the 
WA group in the control site. *P < 0.001, significant vs. WA group; †P < 0.001, significant 





























Figure 4.3 A summary of group cutaneous vascular conductance as a percentage of maximal vasodilation in response to local 
heating across all treatment sites  
Left panels, white Americans; right panels, black Americans. A, the NOS-inhibited site. B, the L-arginine supplemented site. C, 
the arginase-inhibited site. Cutaneous vascular conductance during the rise in local temperature (°C) (%CVCmax) in the control 
site is shown for comparison. L-arginine supplementation improved %CVCmax in black Americans but not white Americans. 
*P < 0.05, significant difference vs. the control site within the groups; †P < 0.05, significant interaction (drug site x temperature). 














































Figure 4.3 A summary of group cutaneous vascular conductance as a percentage of maximal vasodilation in response to local 









































Figure 4.3 A summary of group cutaneous vascular conductance as a percentage of maximal vasodilation in response to local 
heating across all treatment sites (Continued) 
 
 





































Figure 4.4 A summary of NO contribution in response to local heating of skin between 
groups  
Open bars, white American (WA) group; Filled bars, black American (BA) group. The 
difference in cutaneous vascular conductance as a percentage of maximal vasodilation 
(%CVCmax) in response to the rise in local skin temperature (°C) between the control site 
and NOS-inhibited site (Δ %CVCmax) was calculated to assess NO contribution as an 
index of NO bioavailability. NO contribution was lower in the BA group than the WA 
group during local heating of skin. *P < 0.001, significant difference vs. WA group; †P < 
0.05, significant interaction (group x temperature). Values are means ± SE. 
 
  
























Figure 4.5 A summary of group cutaneous vascular conductance as a percentage of 
maximal vasodilation (%CVCmax) for the plateau phase at 42 °C heating of skin in all 
sites  
Open bars, white American (WA) group; Filled bars, black American (BA) group. L-
arginine supplementation improved %CVCmax in the BA group but not the WA group. *P 
< 0.001, significant difference vs. WA group; †P < 0.05, significant difference vs. control 
site in the WA group; ‡P < 0.05, significant difference vs. control site in the BA group. 

































Chapter 5: Study Two 
 
The Effects of Acute Flavanol Intake on Cutaneous Microvascular Function in 




Black Americans have increased risk for cardiovascular disease relative to white 
Americans and the underlying impairments manifest as early as the second generation prior 
to any overt signs of risk. We have recently demonstrated that nitric oxide (NO)-dependent 
microvascular function in response to local heating of skin is attenuated in healthy young 
black Americans relative to white Americans. Thus, we hypothesized that acute 
consumption of flavanol-rich cocoa would restore reduced cutaneous microvascular 
responses to local heating in young black Americans.  
Seven black Americans and seven white Americans participated in this double-
blind crossover study. Data were collected on two different days at the same time each day, 
separated by a minimum of one week. Two intradermal microdialysis membranes were 
inserted in the forearm and skin blood flow was indexed via a laser-Doppler probe housed 
within a local heater over the membrane sites. Each site randomly assigned to receive 
lactated Ringer’s solution or 20 mM NG-nitro-L-arginine (L-NAME). After 
instrumentation, participants were randomly assigned to consume either a non-flavanol 
containing (NF) beverage or flavanol-rich cocoa (FC) beverage. After recovery from the 
insertion trauma, the local heater was clamped at 32 °C for 45 min of baseline data 
collection after which the temperature was increased to 39 °C for 30 min. Finally, maximal 
cutaneous vasodilation was achieved by a combination of infusion of 28 mM sodium 
nitroprusside (SNP) and 43 °C local heating. Cutaneous vascular conductance (CVC) was 
calculated as cutaneous blood flux/mean arterial pressure and normalized as % maximal 
CVC (%CVCmax). The difference in %CVCmax between the control site and L-NAME 
site (Δ %CVCmax) across the rise in skin temperature was calculated to assess NO 
contribution.  
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In Ringer’s site, acute consumption of FC beverage improved the plateau 
%CVCmax at 39 °C heating in the black American group when compared to NF beverage 
(NF: 36 ± 4 vs. FC: 47 ± 4 %CVCmax; P = 0.008) while there was similar %CVCmax at 
39 °C heating between beverages in the white American group (NF: 55 ± 4 vs. F: 59 ± 4 
%CVCmax; P = 0.404). At the plateau (39 °C), NO contribution was significantly higher 
with FC beverage than NF beverage in black Americans (NF: 27 ± 3 vs. F: 35 ± 3 
Δ%CVCmax; P = 0.026) while there was similar NO contribution between beverages in 
white Americans (NF: 42 ± 4 vs. F: 45 ± 4 Δ%CVCmax; P = 0.363) 
The primary finding of this study is that acute consumption of FC improved 
cutaneous microvascular function in response to local heating in young black Americans 
when compare with NF. This data suggests that an attenuated microvascular function in 




Ethnicity is one of the major risk factors of cardiovascular disease (CVD). Research 
has shown that black Americans have, traditionally, experienced higher rates of mortality 
and morbidity from CVD than white Americans for every decennial year back to 1900 [3, 
4, 78]. Black American men and women (44% and 49%, respectively) have higher 
prevalence of CVD than white American men and women (37% and 32%, respectively) 
[79]. Furthermore, CVD prevalence is higher in young black Americans than age-matched 
white Americans (35-44 years) and this racial disparity between young black Americans 
and white Americans may not be explained by clinical and socioeconomic factors [24].  
The explanations for these racial differences between black Americans and white 
Americans adults remain unclear. However, recent studies have shown that endothelial 
dysfunction, because of decreased nitric oxide (NO) bioavailability, play a major role in 
the increased risk for CVD in this population [4, 23, 27]. Given that NO plays a pivotal 
role not only in vasodilation but also platelet aggregation, adhesion of leukocytes to the 
endothelium, and smooth muscle cell proliferation and migration [80], endothelial-derived 
NO acts as an important mediator of cardiovascular homeostasis and vascular tone in 
humans. We have previously demonstrated that NO-dependent vasodilation in 
microvasculature is significantly attenuated in young black American adults relative to age-
matched white American adults. This finding is consistent with previous studies, showing 
impaired vascular function in young black American adults compared with their white 
counterparts [28, 30, 64]. Furthermore, there is compelling evidence that endothelial 
dysfunction in microvasculature is an early predictive marker of CVD [81] and its risk 
factors including hypertension [82] and diabetes mellitus [83]. 
One possible mechanism of decreased NO bioavailability observed in young black 
Americans is upregulation of superoxide (O2
−). Previous studies have shown that the 
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administration of calcium ionophore, an endothelial NO synthase (eNOS) agonist, 
increases O2
− production in human umbilical vein endothelial cells (HUVECs) more in 
black Americans than white Americans. In addition, upregulation of nicotinamide adenine 
dinucleotide phosphate (NADPH) is also observed in black Americans relative white 
Americans [66]. This data suggests that excessive production of O2
− in the endothelial cells 
may lead to decrease in NO bioavailability in black American adults. It is also notable that 
O2
− produced in the endothelial cells rapidly reacts with NO and produce a potent oxidant 
peroxynitrite (ONOO−). ONOO− may lead to the oxidation of proteins, deoxyribonucleic 
acid, and lipids in vascular walls [66]. Thus, increased production of ONOO− due to 
upregulated O2
− may further limit NO bioavailability. 
Diet is a modifiable lifestyle factor that plays a major role in the primary and 
secondary prevention of CVD [84, 85]. Flavonoids are dietary plant-derived bioactive 
ingredients that are abundant in a variety of fruits and vegetables. It has estimated that the 
average daily total flavonoid intake of U.S. adults is 189.7 mg/day that is mainly from 
flavanols (83.5%), flavanones (7.6%), flavonols (6.8%), anthocyanidins (1.6%), flavones 
(0.8%), and isoflavones (0.6%) [86]. Recently, flavanols, a subgroup of flavonoids, have 
gained increasing attention due to its benefits on cardiovascular health. Flavanols are 
abundant in cocoa-containing products, green tea, red wine, and soy products [87]. The 
estimated mean flavanol intake of U.S. adult is in the range of 50-100 mg/day [88]. 
Data from a number of studies have demonstrated that flavanols independently have 
beneficial effects on cardiovascular health. Although the exact underlying mechanisms 
involved in reduced CVD risk factors on flavanol intake have not yet fully understood, 
recent evidence suggest that flavanol intake augments NO bioavailability in the 
endothelium, thus the improvement of endothelial function [89]. In the support of this 
hypothesis, our laboratory recently reported that cerebral vasomotor reactivity in response 
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to a typical rebreathing protocol is reduced in college-aged black Americans relative to 
age-matched white Americans, suggesting an impaired endothelial function in cerebral 
microcirculation [25]. This attenuated cerebral vasodilatory capacity in healthy young 
black Americans was improved with acute flavanol intake [26].  
In addition, the majority of studies have demonstrated that flavanols are related to 
an improvement in larger arteries such as the brachial artery [90-92] while there is 
uncertainty if endothelial function might be restored in the microvasculature following 
flavanol ingestion. Accordingly, the current study aimed to investigate the effects of acute 
flavanol intake on cutaneous microvascular function in young black Americans. We tested 
the hypothesis that acute consumption of flavanol-rich cocoa (FC) beverage would improve 
cutaneous microvascular function in response to local heating in young black Americans 
relative to young white Americans. Furthermore, we hypothesized that the improvement 
of microvascular function with acute flavanol intake is related to increase in NO 








Ethical Approval and Subjects  
Young adults aged 18-30 were recruited for this study. The groups were 
compromised of seven healthy black Americans and seven healthy white Americans 
subjects. All subjects completed a medical history questionnaire prior to participation. 
Ethnicity of each subject was self-defined as black Americans or white Americans, and the 
subject was only accepted if both parents are black Americans or white Americans, 
respectively. Before participation, all experimental procedures were explained to subjects 
and they were given an opportunity to ask questions. All subjects were free from any known 
cardiovascular, neurological, and metabolic diseases, and were non-smokers. All female 
subjects were not on birth control and all experiments were conducted during the early 
follicular phase of their menstrual cycle (days 1-3) to minimalize the fluctuations of female 
hormone, which might affect the endothelial function [51, 52]. 
 
Instrumentation and Measurements 
This study was conducted in the Environmental and Autonomic Physiology 
Laboratory (BEL 846) at the University of Texas at Austin. All subjects were asked to 
report to the temperature-controlled laboratory (22-23 °C) on two different days at the same 
time each day, separated by a minimum of 1 week. All data were collected in the morning 
following at least a 12-hour fast, having refrained from caffeine containing drinks for 12 
hours and strenuous exercise and alcohol drinks for 24 hours. All subjects were asked to 
follow a low-flavanol diet in the three consecutive days prior to each testing day.  
On the first visit, subjects read and signed the Consent to Participate form and filled 
out the Research Health Questionnaire. The height and weight of subjects were obtained 
for calculation of body mass index (BMI). Subjects were then asked to lie down on a 
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patient’s bed in the semi-supine position for the remainder of data collection. Five 
electrodes were attached to the subject for the assessment of cardiac rhythms and heart rate 
(HR) measured via an electrocardiogram (HP Patient Monitor, Agilent, Santa Clara, CA) 
interfaced with a cardiotachometer (CWE, Ardmore, PA). A blood pressure cuff was put 
on the upper arm for the assessment of arterial blood pressure measured from auscultation 
of the brachial artery (Tango+; SunTech, Raleigh, NC). 
Subjects were instrumented with two intradermal microdialysis membranes on the 
ventral surface of the non-dominant forearm (CMA 31 Linear Microdialysis Probe, 55 kDa 
cut-off membrane; CMA Microdialysis AB, Holliston, MA). Once each microdialysis 
membrane was inserted on the skin, each site continuously received lactated Ringer’s 
solution (2 μl/min) via an infusion pump (Pump 11, Harvard Appartus, Natick, MA) [9, 
53, 54]. Two laser-Dopplers (VP7 A/T with moorVMS-LDF2; Moor Instruments, 
Wilmington, DE) housed within 3-cm diameter local heating elements (PeriFlux System 
5000; Perimed, Sweden) were placed above each microdialysis membrane. After the 
placement of laser-Dopplers and local heating elements, the local heaters were clamped at 
32 ºC, and there was a 60-90 min waiting period to allow for the hyperemia associated with 




After the 45 minutes of the 60-90 min waiting period, subjects consumed either a 
FC beverage or a nutrient-matched non-flavanol (NF) beverage (provided in a double 
blinded and randomized fashion). The macro and micronutrient composition of the 
beverages is provided in Table 5.1. A third party person prepared (randomized order), 
appropriately documented, and administered the test beverage keeping it double-blind. The 
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beverage was mixed in 300 ml of water, and subjects were asked to consume the beverage 
within 5 min. Upon completion of the beverage, a timer was immediately started to ensure 
that the second measures of interest are taken as close to a 2 hour post-ingestion. Upon the 
completion of a 60-90 min waiting period, the baseline data were obtained and the 
experimental sites were randomly infused either lactated Ringer’s solution as control or 20 
mM L-NAME to locally inhibit NO production at a rate of 2 μl/min for a 45-min drug 
wash-in period.  Following this drug wash-in period the temperature of each local heating 
element to was raised to 39 ºC at a rate of 0.5 every 5 seconds and was clamped at 39 ºC 
for 30 min, while each site continued to receive its respective solutions. Following this 30 
min period, local temperature was increased to 43ºC, and 28 mM of sodium nitroprusside 
(SNP) was perfused through each site to induce maximal vasodilation [11]. During the 
heating protocol, subjects were asked to keep their non-dominant arm stable. At the end of 
the heating protocol, the heaters were turned off and removed from the skin to minimalize 
the possibility of ‘desensitization’ in the skin with prolonged heating [93-95]. 
 
Data Analysis  
The laser-Doppler flowmetry (LDF) (in flux units) and skin temperature data were 
integrated with a data acquisition system (MP150, BIOPAC Systems, Goleta, CA) and 
recorded on a laboratory computer for off-line analysis (Acknowledge, BIOPAC, Goleta, 
CA). The red blood cell (RBC) flux recorded via LDF in the final minute of each stage 
(baseline at 32 ºC, plateau at 39 ºC, and SNP plus 43 ºC heating) was averaged. In the last 
minute of each stage, blood pressure measurement was also taken via auscultation at the 
brachial artery to calculate mean arterial pressure (MAP) to calculate cutaneous vascular 
conductance (CVC) at each stage. CVC was then presented as a percentage of maximal 
CVC (%CVCmax) that was obtained during combined SNP infusion and 43 ºC local 
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heating. The difference in %CVCmax between the control site and L-NAME site (Δ 
%CVCmax) across the rise in skin temperature was calculated to assess the NO 
contribution as an index of NO bioavailability. 
 
Statistical Analysis 
All data were analyzed using a statistical software package (Stata 13; StataCorp LP, 
College Station, TX). A paired t-test showed no significant differences in physical 
characteristics and hemodynamic variables obtained under fasting conditions during rest 
on each of the experimental days, so these data were averaged. Unpaired Student’s t-tests 
were then performed to detect significant differences between groups for in physical 
characteristics and hemodynamic variables. A three-way repeated measure mixed model 
was conducted to estimate; 1) the effects of group, test beverage, and drug site on absolute 
maximal CVC, 2) the effects of group and test beverage on %CVCmax over a rise in local 
temperature at each drug site, and 3) the effect of group and test beverage on NO 
contribution over a rise in local temperature. A two-way repeated measure mixed model 
was also conducted to estimate the effects of group and test beverage for the plateau 
%CVCmax (39 ºC heating) at the lactated Ringer’s site. The post-hoc comparison with 
Tukey's HSD were performed when a significant interaction was identified. All data are 





Subject Characteristics  
As shown in Table 5.2, subjects were well matched for age, height, weight, and 
BMI (all P > 0.05). Baseline systolic blood pressure (SBP), diastolic blood pressure (DBP), 
MAP, HR, CVC, %CVC were not different between NF and FC in both groups (all P > 
0.05) (Table 5.3). 
 
The Effects of Acute Flavanol Intake on Cutaneous Microvascular Function 
Absolute maximal CVC. Table 5.4 shows absolute maximal CVC during combined 
43 °C heating and 28 mM SNP infusion. Absolute maximal CVC was similar between 
groups and test beverage across all drug sites (all P > 0.05). No significant interactions 
between group and test beverage across all site was observed (P = 0.478). There was no 
significant interaction between group and test beverage (P = 0.476), drug site and test 
beverage (P = 0.812), or group and drug site (P = 0.966). There no significant main effect 
of group (P = 0.575), test beverage (P = 0.766), or drug site (P = 0.175). These data 
confirms that the maximal vasodiatory capacity of the cutaneous microvasculature was not 
different between group and test beverage across all drug sites.  
Ringer’s solution site. Figure 5.1 shows a skin blood flow (SkBF) tracing between 
dietary intervention days from a representative subject in each group. Figure 5.2 
summarizes the SkBF response to the rise in local temperature between group and test 
beverage at the Ringer’s site. There was no statistically significant difference in the 
baseline %CVCmax at 32 °C between NF and FC beverages in both of the white Americans 
group (NF: 11 ± 4 vs. FC: 10 ± 4 %CVCmax; P = 0.735) and the black American group 
(NF: 8 ± 4 vs. FC: 10 ± 4 %CVCmax; P = 0.716). The plateau %CVCmax at 39 °C heating 
with FC beverage improved %CVCmax in the black American group when compared to 
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NF beverage (NF: 36 ± 4 vs. FC: 47 ± 4 %CVCmax; P = 0.008) while there was similar 
%CVCmax at 39 °C between NF and FC beverages in the white American group (NF: 55 
± 4 vs. FC: 59 ± 4 %CVCmax; P = 0.404). No significant three-way interaction was 
observed (P = 0.578). There was a significant interaction between group and temperature 
(P < 0.001) but not between temperature and beverage (P = 0.084) or between group and 
beverage (P = 0.208). The significant interaction between group and temperature remained 
following Bonferroni correction. In the Ringer’s site, there was a significant main effect of 
group (P = 0.017) and temperature (P < 0.001), but not beverage (P = 0.079). 
L-NAME site. Figure 5.3 summarizes the SkBF response to the rise in local 
temperature between group and beverage at the NOS-inhibited site. There was no 
statistically significant difference in the baseline %CVCmax at 32 °C between NF and FC 
beverages in the white American group (NF: 7 ± 1 vs. FC: 7 ± 1 %CVCmax; P = 0.890) or 
in the black American group (NF: 5 ± 1 vs. FC: 6 ± 1 %CVCmax; P = 0.620). At 39 °C 
heating, there was no statistically significant difference in the plateau %CVCmax between 
NF and FC beverages in the white American group (NF: 13 ± 1 vs. FC: 13 ± 1 %CVCmax; 
P = 0.919) or in the black American group (NF: 10 ± 1 vs. FC: 12 ± 1 %CVCmax; P = 
0.158). In the L-NAME site, there was no significant interaction between group and 
temperature (P = 0.565), between temperature and beverage (P = 0.634), or between group 
and beverage (P = 0.283). There was a significant main effect of temperature (P < 0.001), 
but not group (P = 0.127) or beverage (P = 0.404). 
NO contribution. Figure 5.4 shows NO contribution between groups. At the 
baseline (32 °C), there were no differences in NO contribution between NF and FC 
beverages in the white American group (NF: 5 ± 3 vs. FC: 2 ± 3 Δ %CVCmax; P = 0.688), 
or in the black American group (NF: 3 ± 3 vs. FC: 4 ± 3 Δ %CVCmax; P = 0.850). At the 
plateau (39 °C), NO contribution was significantly higher with FC beverage than NF 
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beverage in the black American group (NF: 27 ± 3 vs. FC: 35 ± 3 Δ %CVCmax; P = 0.028) 
while there was similar NO contribution between NF and FC beverages in the white 
American group (NF: 40 ± 4 vs. FC: 44 ± 4 Δ %CVCmax; P = 0.307). No significant three-
way interaction was observed (P = 0.829). There was a significant interaction between 
group and temperature (P = 0.007), but not between temperature and beverage (P = 0.086) 
or between group and beverage (P = 0.419). There was a significant main effect of 
temperature (P < 0.001) but not group (P = 0.054) or beverage (P = 0.128). 
%CVCmax for the plateau at the Ringer’s site. Figure 5.5A displays mean 
%CVCmax for the plateau phase at 39 °C heating of skin between young black Americans 
and white Americans at the Ringer’s site. The plateau %CVmax at 39 °C heating was a 
significantly lower in the black American group than the white American group with NF 
beverage (black American (BA): 36 ± 5 vs. white American (WA): 55 ± 5 %CVCmax; P 
= 0.004). In the black American group, this attenuated %CVCmax at 39 °C heating 
improved to the level of the white American group by acute FC intake (BA: 47± 5 vs. WA: 
59 ± 5 %CVCmax; P = 0.082). No interaction between group and beverage was observed 







The aim of the current study was to investigate the effects of acute flavanol intake 
on cutaneous microvascular function in response to local heating and to determine if the 
response to heating with acute flavanol intake differs between young black Americans and 
white Americans. The major findings of this study is that acute consumption of FC 
improved cutaneous microvascular function in response to local heating in young black 
Americans when compare to NF, and that such improvement of cutaneous microvascular 
function in young black Americans was related to increase in NO bioavailability.  
To our knowledge, no study has specifically investigated the effects of acute 
consumption of FC on cutaneous microvascular function in young black Americans. 
However, the outcomes of this study are similar to our previous study on cerebral 
vasomotor reactivity, showing that attenuated cerebral vasodilatory capacity in healthy 
young black Americans improved with acute consumption of FC when compared to age-
matched white Americans [26]. Furthermore, it is important to note that our findings are 
consistent with previous studies in other populations. It has been reported that acute and 
long-term supplementation of flavanols improve endothelial function in healthy 
individuals [96] and this effect is augmented individuals with endothelial dysfunction [90, 
92, 97]. It has also shown that consumption of flavanol-containing food and beverages 
including dark chocolate, black tea, and red wine improved vasodilatory responses in 
individuals with coronary artery disease [98], hypertension [99], kidney disease [100], and 
type II diabetes [92]. 
NO is synthesized in the endothelial cells in the presence of the cofactor 
thetrahydrobiopterin (BH4) by the reaction of eNOS, which divide the substrate L-arginine 
into NO and L-citrulline. NO acts as a primary vasoactive substance that plays a critical 
role in vasodilation [31]. NO bioavailability is detectable based on the balance between the 
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synthesis and degradation of NO in the vasculature. The underlying mechanisms of the 
improved endothelial function by the supplementation of flavanols in young black 
Americans has not been fully explored. However, given that endothelial dysfunction due 
partly to decrease in NO bioavailability is commonly observed in black Americans [23, 66, 
101], it is reliable to suggest that the improvement of endothelial function is related to an 
increase in NO bioavailability in young black Americans. Indeed, in the current study, we 
found that the improvement of cutaneous microvascular function with acute flavanol intake 
in young black Americans was related to an increase in NO bioavailability. 
The exact mechanisms by which flavanols affect NO bioavailability are unknown 
and require further investigation to mechanistically explain the findings in the present 
study; however, given that black American population commonly have higher oxidative 
stress levels than other racial groups, it is plausible that flavanols might scavenge free 
radicals including O2
− and contribute to increase in NO bioavailability. It has been reported 
that reduced NO bioavailability in young black Americans (22 years) is related to the 
superoxide anion [66], which leads to a reduction in NO bioavailability as they react with 
NO to form ONOO– [69, 70]. Similarly, Manson et al. (2005) have shown that NO 
production is improved by a NADPH oxidase inhibitor in young black Americans [102]. 
Additionally, studies have demonstrated that epicatechins, primary monomer of flavanols, 
reduce the production of free radicals including O2
− through of NADPH oxidase, in turn, 
improves NO bioavailability [103, 104]. Thus, it is possible that an elevated production of 
O2
− due to upreguation of NADPH oxidase may lead to decrease in NO bioavailability and 
microvascular dysfunction in young black Americans, and that flavanols may affectively 
reduce the production of O2
− by decreasing NADPH oxidase activity and improve NO 
bioavailability in young black American individuals. 
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Another potential mechanism of improved NO bioavailability associated with 
flavanols in young black Americans is the improvement of eNOS coupling by indirect 
pathways, including upregulation of eNOS activity, inhibition of arginase activity, and/or 
improvement of L-arginine availability in the endothelial cells. In vitro studies, endothelial 
cells incubated with flavonoid-rich red wine upregulated eNOS mRNA and protein 
expression, producing more bioactive NO (up to 3 times) than the control cells [105]. Plant 
extracts rich in flavonoids also upregulated eNOS activity in cultured endothelial cells 
[106, 107] and rat aorta [108]. Furthermore, cocoa flavanols also reduced arginase activity 
in human endothelial cells, leading to increase in local concentrations of the substrate, L-
arginine [109]. Thus, we suggest the possibility that the improvement of cutaneous 
microvascular function associated with flavanols observed in young black Americans may 
be exerted via the direct reduction of free radicals including O2
− and/or the indirect 
upregulation of eNOS activity. 
In young white American individuals, the acute consumption of FC did not show 
any statistically significant improvement on cutaneous microvascular function in response 
to local heating compared with NF. The reasons for this can be multifactorial; however, it 
can be speculated that young and healthy white American individuals did not have any 




Cutaneous thermal hyperemia can be observed via local heating of the skin, which 
leads to a rapid vasodilation. In a typical local heating protocol, thermally-induced 
hyperemia response to 42 °C heating of skin at a rate of 0.1 °C/s has been widely used to 
assess NO-dependent vasodilation in microvasculature. Local heating of skin elicits 
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cutaneous blood flow reactivity in two distinct phases that is marked by an initial peak in 
SkBF within the first 5 min of heating and is followed by a plateau which is reached within 
30 min of heating [43, 62, 110-112]. However, it is important to note that the plateau phase 
in response to local heating of skin is dependent not only NO but also endothelium-derived 
hyperpolarizing factors (EDHFs). Approximately 50-60% of vasodilation on the plateau 
phase is dependent on NO [62, 113] through transient receptor potential vanilloid type-1 
(TRPV1) channels [114], adenosine receptors [115], and reactive oxygen species [116] 
while the remaining 40-50% depends on EDHFs that stimulate calcium-activated 
potassium channels on endothelial and smooth muscle cells [110]. 
For this reason, we applied a 39 °C heating to elicit cutaneous thermal hyperemia, 
which is mostly dependent on NO but not EDHFs. Choi et al. (2014) have recently 
demonstrated that reducing the target temperature from 42 °C to 39 °C during a local 
heating protocol elicit a hyperemic response that is approximately 80% dependent on NO 
[117]. In the current study, the plateau %CVCmax obtained by 39 °C heating was 76% 
dependent on NO in the white Americans group and 72% dependent on NO in the black 
American group when consumed NF beverage (data not shown). Thus, we believe that the 
findings from the current study might be more reliable evidence than others to assess NO-




The present study was limited by the fact that we quantified NO contribution during 
heating by calculating the difference between %CVCmax at the control site and L-NAME 
site (Δ %CVCmax). Previously, several microdialysis studies have coinfused nonspecific 
NOS inhibitor L-NAME within the experimental sites to quantify NO-dependent 
vasodilation during a standardized local heating protocol, which the skin is needed to be 
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heated for a 70–90 min continuously [49, 62, 113, 118]. However, Hodges et al. (2008) 
have suggested that an extended length of time on local heating protocol may result in a 
“die-away phenomenon”, attributing to a reduction in vasodilation [55]. In line with that, 
although we did not quantify NO contribution within each microdialysis, we did evaluate 
the time course of the interventions with < 60 min of local heating.  
The present study was a double-blind cross-sectional study with a small sample 
size; thus, our results that black American improved cutaneous microvascular function with 
acute flavanol intake may include a type 2 error. However, we observed an increased 
microvascular function with flavanol intake in most of seven black American individuals, 
so it was not being skewed by an outlier (Fig. 5.5B). Additional data in larger groups may 
help to confirm our findings. 
In the present study, we did not analyze blood sample including plasma flavanol 
metabolites, nitrate/nitrite, and oxidized low density lipoprotein to verify whether flavanols 
were present in the circulation or if there was an effect of flavanols on NO bioavailability. 
However, a 2-hour window was chosen in the present study. Several studies with flavanol 
ingestion have demonstrated that plasma concentration of flavanols peak after 2 hours from 
the ingestion [92, 119-122]. Furthermore, we believe that the flavanol content in FC 
beverage (792 mg) used in the present study was high enough to elicit the benefits of acute 




This study demonstrated that acute consumption of FC improves cutaneous 
microvascular function in young black American relative to age-matched white Americans. 
Furthermore, this study demonstrated that the improvement of cutaneous microvascular 
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function with flavanols is related to an increase in NO bioavailability. Considering that 
young black American adults have attenuated NO-dependent vasodilation in 
microvasculature and that acute consumption of FC restores cutaneous microvascular 
function in young black American adults, flavanol-rich beverage and food could be a novel 
potential therapeutic target to delay onset of microvascular dysfunction and prevent the 




5.6 TABLES AND FIGURES 
 
Table 5.1 Product nutrition facts 
 
Per serving Flavanol Non-flavanol 
Calories 224 229 
Fat, g (calculated) 3 0 
Sat fat, g 1.5 0 
Trans fat, g 0 0 
Cholesterol, mg 16.5 18 
Sodium, mg 546 555 
Carbohydrates, g 37.5 39 
Dietary fiber, g 7.5 7.5 
Sugar, g 25.5 30 
Protein, g 21 21 
Vitamin A, IU 15 12 
Vitamin C, mg 3 4.5 
Calcium, mg 643.5 729 
Iron, mg 1.5 0 
Magnesium, mg 169.5 61.5 
Potassium, mg 1170 1014 
Flavanols 1-10, mg 370.8 0.0 
Monomers 97.2 0.0 
Catechin, mg 26.7 0.0 
Epicatechin, mg 70.5 0.0 
2-10 mers 273.6 0.0 
Total flavanols, mg* 729.0 0.0 
 
  * Total flavanols include all flavanols that are greater than 10 polymers. 
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Table 5.2 Subject characteristics  










Age (years) 22 ± 4 22 ± 4 0.89 
Sex (M/F) 4/3 4/3 1.00 
Height (cm) 171 ± 11 169 ± 10 0.82 
Weight (kg) 70 ± 14 69 ± 13 0.92 




Table 5.3 Baseline hemodynamic variables  
NF, beverage without flavanols, FC, flavanol-rich cocoa beverage; HR, heart rate; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; 
CVC, cutaneous vascular conductance; %CVCmax: CVC as a percentage of maximal 
vasodilation. All data were collected in the last minute of baseline period at the Ringer’s 
solution site. Baseline hemodynamics were not different between NF and FC in both 




White American Black American 
 NF FC NF FC 
HR (beats/min) 59 ± 9 59 ± 8 67 ± 8 65 ± 7 
SBP (mmHg) 110 ± 8 114 ± 6 120 ±12 120 ± 5 
DBP (mmHg) 69 ± 4 67 ± 7 71 ± 13 71 ± 7 
MAP (mmHg) 83 ± 4 82 ± 4 87 ± 10 87 ± 5 
CVC (flux/mmHg) 0.34 ± 0.13 0.28  ± 0.08 0.23 ± 0.19 0.28 ± 0.14 




Table 5.4 Absolute maximal cutaneous vascular conductance (CVC) across all sites  
L-NAME, NG-nitro-L-arginine. NF, beverage without flavanols; FC, flavanol-rich cocoa 
beverage. Absolute maximal CVC was similar between groups and test beverages across 
all sites (all P > 0.05). No significant interaction between group and test beverage across 




 White American Black American 
 NF FC NF FC 
Control site 3.21 ± 0.27 3.03 ± 0.27 2.85 ± 0.27 3.04 ± 0.27 





Figure 5.1 A skin blood flow tracing from a representative black American subject  
LDF, laser-Doppler flowmetry. NF, beverage without flavanols; FC, flavanol-rich cocoa 
beverage. A, initial peak; B, plateau; C, maxial SkBF induced by SNP. Data selected from 








































Figure 5.2 A summary of the skin blood flow response to the rise in local temperature between group and test beverage at the 
ringer’s site 
Left panel, white Americans; right panel, black Americans. NF, beverage without flavanol; FC, flavanol-rich cocoa beverage. 
Acute consumption of FC improved %CVCmax in black Americans but not white Americans when compare to NF. There was 
a significant interaction (group and temperature) (P < 0.001) but not (temperature and beverage) (P = 0.084). *P < 0.05, 












































Figure 5.3 A summary of the skin blood flow response to the rise in local temperature between group and test beverage at the 
L-NAME site  
Left panel, white Americans; right panel, black Americans. NF, beverage without flavanol; FC, flavanol-rich cocoa beverage. 
%CVCmax was similar between NF and FC in each group (all P > 0.05). There was no significant interaction between group 
and temperature (P = 0.565), between temperature and beverage (P = 0.634), or between group and beverage (P = 0.283). Values 









































Figure 5.4 A summary of NO contribution in response to local heating of skin 
Left panel, white Americans; right panel, black Americans. The difference in cutaneous vascular conductance as a percentage of 
maximal vasodilation in response to the rise in local skin temperature (°C) between the control site and NOS-inhibited site (Δ 
%CVCmax) was calculated to assess NO contribution as an index of NO bioavailability. NO contribution was lower in the black 
American group than the white American group during local heating of skin. There was a significant interaction between group 
and temperature (P = 0.007) but not between temperature and beverage (P = 0.086). *P < 0.001, significant difference vs. NF. 









































Figure 5.5 A summary of %CVCmax for the plateau phase at 39 °C heating of skin between young black Americans and white 
Americans at the Ringer’s site  
A, the plateau %CVCmax at 39 °C heating between groups; B, individual %CVCmax at 39 °C heating between non-flavanol 
(NF) and flavanol-rich cocoa (FC) beverages in black American group. Open bar, white American (WA) group with NF; black-
colored bar, black American (BA) group with NF; grey-colored bar, WA group with FC, pattern-filled bar, BA group with FC. 












































Chapter 6: Study Three 
 
The Effects of Acute Flavanol Intake on Methacholine-induced Cutaneous 




Black American adults have increased morbidity and mortality stemming from 
cardiovascular disease and related risk factors relative to white American adults. 
Furthermore, it is known that the underlying impairments manifest early in young adults 
prior to any overt signs of risk in this population. We have recently demonstrated that nitric 
oxide dependent cutaneous microvascular function is attenuated in young black Americans 
relative to age-matched white Americans. Thus, we hypothesized that young black 
Americans would have an attenuated vasodilatory response to methacholine (MCh)-
induced cutaneous vasodilation when compare to age-match white Americans as indexed 
by the dose of MCh required to elicit 50% of the maximal vasodilation (EC50). We also 
tested the hypothesis that acute consumption of flavanol-rich cocoa (FC) would produce a 
leftward shift in the dose-response curve of MCh-induced cutaneous vasodilation in young 
black Americans, while there would be no effects of acute consumption of FC in young 
white Americans. 
Fourteen young adults (7 black Americans and 7 white Americans) participated in 
this double-blind crossover study. Data were collected on two different days, separated by 
a minimum of one week. A single intradermal microdialysis membrane was inserted in the 
forearm and skin blood flow was indexed via a laser-Doppler probe housed within a local 
heater over the membrane site. After the placement of the laser-Doppler probe and local 
heater, the local heater was clamped at 32 ºC, and there was a 60-90 min waiting period to 
while the hyperemia associated with the the needle insertion subsided. After a 60-90 min 
waiting period, subjects were randomly assigned to consume either a non-flavanol 
containing (NF) beverage or FC beverage. It was followed a 75-min waiting period as close 
to a 2-hour post-ingestion. Following a 75-min waiting period, the microdialysis site 
received with increasing concentration of MCh (1 x 10-6 M; 7 doses at 10-fold increments) 
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disserved in lactated Ringer’s solution, with each dose being administered for 6 min at 
perfusion rate of 2 μl/min. After the last dose of MCh, local skin temperature was raised 
and clamped at 43 ºC, and 28 mM of sodium nitroprusside (SNP) was perfused for 
approximately 30 min to induce maximal vasodilation. Cutaneous vascular conductance 
(CVC) was calculated as cutaneous blood flux/mean arterial pressure and normalized as a 
percentage of maximal CVC (%CVCmax). A four-parameter logistic curve fit was 
constructed to compare does-reseponse curves of MCh-induced vasodilation between 
groups or test beverages with an extra sum of squares F-test. 
The dose response curves on %CVCmax between the white American group and 
the black American group in each dietary intervention were similar (all P > 0.05). In the 
white Americans group, the dose response curves on %CVCmax were similar (P = 0.869) 
between NF and FC beverages. The log EC50 of dose-response curves on %CVCmax for 
NF and FC were not significantly different (NF: -3.64 ± 0.63 vs. FC: -4.06 ± 0.19 log EC50; 
P = 0.720). In the black Americans group, the dose response curves on %CVCmax were 
similar between NF and FC intake (P = 0.322). The log EC50 for non-flavanol and flavanol 
were not significantly different (NF: -4.12 ± 0.19 vs. FC: -4.09 ± 0.19 log EC50; P = 0.516).  
Contrary to our hypotheses, the log EC50 of dose-response curves on %CVCmax 
was similar between the white American group and the black American group. 
Furthermore, the acute consumption of FC did not alter the dose-response curves of MCh-
induced cutaneous vasodilation in both groups. This data suggests that 1) cutaneous 
microvascular endothelial function in response to incremental doses of MCh might remain 
intact in both black American and white American adults, and 2) acute consumption of FC 






Black American adults are at increased morbidity and mortality of cardiovascular 
disease (CVD) and its risk factors including myocardial infarction [123, 124], stroke [125], 
hypertension and type 2 diabetes [3, 126] when compare to white American adults. One 
potential mechanism of higher morbidity and mortality of CVD in black Americans is 
endothelial dysfunction. Endothelial dysfunction in conduit vessels is commonly observed 
in young black Americans without any overt sign of CVD. Several studies have provided 
evidence that endothelial dysfunction is linked with increased CVD risks in young black 
Americans and other populations. Bassett et al. (1992) investigated vasodilatory capacity 
in normotensive young black and white Americans. They reported that vasodilatory 
capacity of the forearm resistance vessels is lower in young black American men when 
compared to young white American men [28]. Similarly, Campia et al. (2002) 
demonstrated that black American adults have blunted endothelium-dependent and -
independent vasodilation of the brachial artery indexed by flow-mediated dilation and 
nitroglycerin-mediated dilation relative to white American adults [127]. Taken together, 
these findings indicate an early onset of endothelial dysfunction in young black Americans 
prior to any overt signs of risk compared with young white Americans.  
Although most studies of endothelial function in human vessels have focused on 
macrovessels by using plethysmography, there is an emerging evidence that endothelial 
dysfunction presents in microcirculation prior to the macrocirculation. Recently, it has been 
recognized that the microcirculation is an ideal location to predict CVD risk. There is 
compelling evidence that endothelial dysfunction in microvasculature is an early predictive 
marker of CVD events [128, 129] including hypertension and diabetes [130]. To support 
these previous findings we have recently demonstrated that nitric oxide (NO)-dependent 
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vasodilation in cutaneous microvasculature is significantly attenuated in young black 
Americans relative to age-matched white Americans, indicating the present of 
microvascular endothelial dysfunction in young black Americans. 
Diet is one of the modifiable lifestyle factors that has a pivotal role in the prevention 
of CVD and its risk factors [84, 85]. Flavonoids are present in more than 5,000 plants in 
nature that are classified based on their chemical structure. They are usually subdivided 
into several subgroups according to which functional groups are attached to the ‘C-ring’ of 
this 3-ring carbon backbone [131]. The main subgroups of flavonoids include flavanols 
(cocoa, tea, fruits, and wine), flavonols (broccoli, onion, tea, and tomato), flavones (herbs), 
isoflavones (soybean), flavanones (juices), and anthocyanidins (berries and wine) [87]. 
Flavonoids are digested mainly in the small intestine and the liver. Flavonoids metabolites, 
which are chemically and structurally distinct from flavonoids, reach the target tissues 
through blood circulation [131, 132] and each subgroup of flavonoids leads to different 
physiological effects on cardiovascular health [133, 134]. 
Flavanols, a subgroup of flavonoids, have recently gained emerging interest 
because it has been shown that flavanols have beneficial effects on cardiovascular health. 
Research has shown that flavanols independently have beneficial effects on cardiovascular 
health [85, 92]. The exact underlying mechanisms of decreased CVD and its risk factors 
with flavanols have not been fully elucidated; however, recent evidence suggest that 
flavanols increases NO bioavailability in the endothelium and improve endothelial function 
[89]. Furthermore, we have recently found that cerebral vasomotor reactivity in response 
to hypercapnia is attenuated in college-aged black Americans relative to age-matched white 
Americans, suggesting an impaired endothelial function in cerebral microcirculation [25], 
and such attenuated cerebral vasodilatory capacity in young black Americans improved 
with acute flavanol intake [26].  
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Thus, we hypothesized that 1) young black Americans might have a increased 50 
% of the maximal response (EC50) of dose-response curve on methacholine (MCh)-induced 
cutaneous vasodilation when compare to age-match white Americans, and 2) acute 
consumption of flavanol-rich cocoa (FC) would produce a leftward shift in the dose-
response curve of MCh-induced cutaneous vasodilation in young black Americans, while 
there would be no effects of acute consumption of FC in young white Americans.  
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6.3 METHODS 
Ethical Approval and Subjects  
Healthy, young adults aged 18-30 were recruited for this study. The groups were 
compromised of 7 black American and 7 white American subjects. All subjects completed 
a questionnaire on medical history, medications, and lifestyle behaviors prior to 
participation including some optional questions about their ethnic background as well as 
that of their birth parents. Ethnicity of each subject was self-defined as black American or 
white American, and the subject was only accepted if both parents are black American or 
white American, respectively. Before participation, all experimental procedures were 
explained to subjects and they were given an opportunity to ask questions. All subjects 
were not taking any medications known to alter cardiovascular function. Subjects were 
normally active with no history of cardiovascular, metabolic, or neurological disease.  
Current smokers or individuals who quit smoking within the prior two years were excluded 
[50]. All female subjects were only studied during the early follicular phase (within 1-3 
days of the start of menstruation) to minimize the effects of female sex hormones [51, 52].  
 
Instrumentation and Measurements 
This study was completed during two different visits conducted at the same time of 
day, separated by the minimum of one week. Each subject was instrumented with a single 
intradermal cutaneous microdialysis membrane. The membrane was dedicated for the local 
infusion of lactated Ringer’s solution. On each experimental day, subjects reported to the 
Environmental and Autonomic Physiology Laboratory (BEL 846) inside Belmont Hall at 
The University of Texas at Austin, having refrained from strenuous exercise and alcohol 
beverages for 24 hr and from caffeine and food for 12 hr. Subjects were asked to follow a 
low-flavanol diet in the three consecutive days prior to each testing day to control dietary 
 71 
intake of flavanols. On the first visit, subjects read and signed the Consent to Participate 
form and filled out the Research Health Questionnaire. In this time, subjects were 
encouraged to ask any questions regarding the experimental protocol. Then, height and 
weight were obtained in both days to provide subject’s baseline characteristics (Seca 763, 
Seca, Chino, CA). 
Subjects were then asked to lie quietly down on the patient’s bed in the semi-supine 
position for the remainder of data collection. Five electrodes were attached to the subject 
for the assessment of cardiac rhythms and heart rate (HR) measured via an 
electrocardiogram (HP Patient Monitor, Agilent, Santa Clara, CA) interfaced with a 
cardiotachometer (CWE, Ardmore, PA). A blood pressure cuff was put on the upper arm 
for the assessment of arterial blood pressure measured from auscultation of the brachial 
artery via electrosphygmomanometry (Tango+; SunTech, Raleigh, NC). 
Subjects were instrumented with a single intradermal microdialysis membrane 
(CMA 31 Linear Microdialysis Probe, 55 kDa cut-off membrane; CMA Microdialysis AB, 
Holliston, MA) in the dermal space of the dorsal forearm. After the placement of the 
microdialysis membrane, the site was perfused lactated Ringer’s solution at rate of 2 μl/min 
via an infusion pump (Pump 11, Harvard Appartus, Natick, MA) [54-56]. Then, the local 
skin blood flow was continuously measured via a laser-Doppler flowmetry (LDF) probe 
(VP7 A/T with moorVMS-LDF2; Moor Instruments, Wilmington, DE) housed within a 3-
cm diameter local heater (PeriFlux System 5000; Perimed, Sweden), which was placed 
above the microdialysis membrane. After placement of the laser-Doppler and local heater, 
the local heater was clamped at 32 ºC, and there was a 60-90 min waiting period to subside 





Following a 60-90 min waiting period, subjects consumed either a FC beverage or 
a nutrient-matched placebo beverage with the exception that it contained no flavanols (NF), 
randomly. Energy, minerals, and other nutrient components of NF and FC beverage are 
presented in Table 6.1. A third party person prepared (randomized order), appropriately 
documented, and administered the test beverage keeping it double-blind. The beverage was 
mixed in 300 ml of water, and subjects were asked to finish consuming the beverage within 
5 min. Upon completion of the beverage, a timer was immediately started to ensure that 
the second measures of interest were taken as close to a 2-hour post-ingestion. Following 
a 75-min waiting period, the microdialysis site received increasing concentrations of MCh 
(1 x 10-6 M; 7 doses at 10-fold increments) dissolved in lactated Ringer’s solution, with 
each dose being administered for 6 min at perfusion rate of 2 μl/min. This approach has 
been commonly used for dose-response studies to construct dose- response curve and to 
estimate the effective concentration of EC50 [135-137]. After the last dose of MCh, local 
temperature was raised to 43 ºC at a rate of 0.5 every 5 seconds and clamped at 43ºC 
combined with infusion of 28 mM of sodium nitroprusside (SNP) for approximately 30 
min through the microdialysis membrane to induce maximal vasodilation. At the end of 
local skin heating at 43 ºC, the heating element was turned off and removed from the skin 
to minimalize the possibility of ‘desensitization’ in the skin with prolonged heating [93, 
94]. 
 
Data Analysis  
The LDF (in flux units) and skin temperature data were integrated with a data 
acquisition system (MP150, BIOPAC Systems, Goleta, white Americans), and recorded on 
a laboratory computer for off-line analysis (Acknowledge, BIOPAC, Goleta, white 
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Americans). The red blood cell flux recorded via LDF in the final minute of each stage 
(baseline, each dose, and SNP at 43 ºC) was averaged. In the last minute of each stage, 
blood pressure was also obtained via auscultation at the brachial artery to calculate mean 
arterial pressure (MAP), which was used to calculate cutaneous vascular conductance 
(CVC) at each stage. CVC was then presented as a percentage of maximal CVC 
(%CVCmax), which was obtained during 43 ºC heating plus 28 mM SNP infusion. A four-
parameter logistic curve fit in non-linear regression model was constructed to compare 
does-reseponse curves of MCh-induced vasodilation between groups or test beverages with 
an extra sum of squares F-test. 
 
Statistical Analysis 
A paired t-test showed no significant differences in physical characteristics and 
hemodynamic variables obtained under fasting conditions during rest on each of the 
experimental days, so these data were averaged. Analysis of physical characteristics and 
hemodynamic variables between racial groups was performed using independent t-tests. A 
three-way mixed model was conducted to estimate the effect of group, MCh dose, and test 
beverage on the %CVCmax. Both the main effects of group, MCh dose, and test beverage 
and the interaction between group, MCh dose on each test beverage were assessed (Stata 
13; StataCorp LP, College Station, TX). Dose-response curves for %CVCmax was 
constructed using a nonlinear fitting technique for identification of log EC50 for each 
subject (Prism, Graphpad Software). The mean log EC50 of MCh dose-response curves 
between race or test beverages was then compared with an extra sum of squares F-test. The 
post-hoc comparison with Tukey's HSD were performed when a significant interaction was 
identified. All data are presented as means ± SE unless otherwise stated. The level of 




As shown in Table 6.2, subjects were well matched for age, height, weight, and 
body mass index (all P > 0.05). Resting systolic blood pressure (SBP), diastolic blood 
pressure (DBP), MAP, and HR were not different between groups. (all P > 0.05) (Table 
6.3). 
 
The Effects of Acute Flavanol Intake on Cutaneous Microvascular Function 
No statistically significant differences in absolute CVC and %CVCmax in response 
to MCh were observed between male and female for either the white American or the black 
American groups; thus, the data from both sexes in each group were combined. 
Baseline %CVCmax at 32 °C. Table 6.4 shows the baseline %CVCmax between 
post ~10 min and post ~2 hr beverage intake in both groups. In the white American group, 
the baseline %CVCmax was similar between at the beginning of dietary intervention 
protocol (NF: 12 ± 2 vs. FC: 10 ± 2 %CVCmax; P = 0.870) and approximately 2 hr after 
beverage given (NF: 11 ± 2 vs. FC: 11 ± 2 %CVCmax; P = 0.922). In the black American 
group, the baseline %CVCmax was similar between at the beginning of dietary intervention 
protocol (NF: 7 ± 2 vs. FC: 8 ± 2 %CVCmax; P = 0.682) and approximately 2 hr after 
beverage given (NF: 7 ± 2 vs. FC: 8 ± 2 %CVCmax; P = 0.639). No racial difference in 
the baseline %CVCmax was observed either at the beginning of dietary intervention 
protocol between NF and FC beverages (NF: P = 0.101; FC: P = 0.433 respectively) or 
approximately 2 hr after beverage given (NF: P = 0.137; FC: P = 0.277), respectively. No 
significant three-way interaction (group, time, and beverage) was observed (P = 0.745). 
There were no interactions between group and time, time and beverage, or beverage and 
group (all P > 0.05). There was no main effect of group (P = 0.115), time (P = 0.636), or 
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beverage (P = 0.989). This data indicates that the baseline %CVCmax either at the 
beginning of dietary intervention or 2 hr after beverage given was the same between NF 
and FC; thus, we used %CVCmax at approximately 2 hr after beverage given as the 
baseline %CVCmax on each dose-response curve. 
MCh-induced and SNP-induced absolute maximal CVC. Figure 6.1 shows that 
absolute maximal CVC at the highest dose (1M) of MCh and 43 °C heating + 28 mM SNP 
infusion. In white Americans, absolute maximal CVC was similar either maximal dose of 
MCh (NF: 3.0 ± 0.3 vs. FC: 3.2 ± 0.3 flux·mm Hg-1; P = 0.319) or 43°C heating + 28 mM 
SNP infusion (NF: 3.3 ± 0.3 vs. FC: 3.5 ± 0.3 flux·mm Hg-1; P = 0.475). In black 
Americans, absolute maximal CVC was similar either maximal dose of Mch (NF: 2.8 ± 0.3 
vs. FC: 2.7 ± 0.3 flux·mm Hg-1; P = 0.661) or 43°C heating + 28 mM SNP infusion (NF: 
2.9 ± 0.3 vs. FC: 3.1 ± 0.3 flux·mm Hg-1; P = 0.589). No racial difference in absolute 
maximal CVC was observed either at maximal dose of Mch between NF and FC beverages 
(NF: P = 0.711; FC: P = 0.193 respectively) or at 43 °C heating + 28 mM SNP infusion 
between NF and FC beverages (NF: P = 0.397; FC P = 0.337 respectively). No three-way 
interaction was observed (P = 0.529). There were no interactions between group and time, 
time and beverage, or beverage and group (all P > 0.05). There was no main effect of group, 
time. Or beverage (all P > 0.05). This data indicates that the maximal cutaneous 
vasodilation in microvasculature occurred with maximal dose of MCh alone when compare 
to SNP infusion, and was not different between black Americans and white Americans or 
NF and FC beverages. 
Dose response curves on %CVCmax. Figure 6.2 shows endothelium-dependent 
vasodilation in response to incremental dose of MCh. MCh dose-response curves for NF 
and FC intake were compared to evaluate endothelium-dependent vasodilation in the black 
American and white American groups, respectively. In the white American group, the 
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dose-response curves on %CVCmax were similar between NF and FC beverages (P = 
0.869). The log EC50 was not significantly different between NF and FC beverages (NF: -
3.64 ± 0.63 vs. FC: -4.06 ± 0.19 log EC50; P = 0.720). HillSlope was similar between NF 
and FC beverages (P = 0.720). Top and bottom were also not different between NF and FC 
beverages (P = 0.104 and P = 0.687, respectively). In black American group, the dose 
response curves on %CVCmax were similar between NF and FC beverages (P = 0.322). 
The log EC50 was not significantly different between NF and FC beverages (NF: -4.12 ± 
0.19 vs. FC: -4.09 ± 0.19 log EC50; P = 0.516). HillSlope was similar between NF and FC 
beverages (P = 0.130). Top and bottom were also not different between NF and FC 
beverages (P = 0.659 and P = 0.652, respectively). The dose-response curves on 
%CVCmax between white Americans and black Americans in each test beverage were 





The primary aim of this study was to clarify the effects of acute flavanol intake on 
cutaneous microvascular function between young black American and white American 
individuals. In the present investigation, we hypothesized that 1) young black Americans 
might have an increased EC50 of dose-response curve on MCh-induced cutaneous 
vasodilation when compare to age-match white Americans, and 2) acute consumption of 
FC beverage would produce a leftward shift in the dose-response curve of MCh-induced 
cutaneous vasodilation in young black Americans, while there would be no effects of acute 
flavanol intake in young white Americans. Contrary to our hypotheses, the EC50 of dose-
response curve on MCh-induced cutaneous vasodilation was similar between racial groups. 
Furthermore, the acute consumption of FC beverage did not alter the dose-response curve 
on MCh-induced cutaneous vasodilation in both races. 
 It is well demonstrated that black Americans have reduced endothelial function in 
response to a variety of stimuli. Forearm blood flow (FBF) responses to exercise [28], 
ischemia [63], and mental stress [64] were significantly lower in healthy black Americans 
when compare to healthy white Americans. Cardillo et al. (1999) have also reported that 
FBF was attenuated in young black Americans following separate infusions of 
isoproterenol [138]. However, several cautions must be taken in interpreting our results in 
light of these previous studies. It has been reported that there is some heterogeneity in 
arteries in endothelial and smooth muscle cell in regards to shape and function [139, 140]. 
Galle et al. (1993) have also demonstrated that different sized vessels exhibit 
heterogeneous vasodilatory responses [141]. Importantly, it is notable that laser Doppler-
induced indices of cutaneous microcirculation do not correlate with conduit vessel response 
to flow-mediated dilation either in control subjects or in a coronary artery disease patients 
[142]. Furthermore, the use of iontophoresis technique has received considerable attention. 
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The iontophoresis technique used in Cardillo’s study requires infusing vasoactive 
substances into intradermal space by using electrical charges. It has been indicated that 
non-specific effects of the electrical charges and individual differences in skin electrical 
resistance could influence the responses to intradermal drug infusion by iontophoresis. 
These factors can confound the results and make it difficult to ensure if vasoactive 
substances are actually delivered into intradermal space by this technique [143, 144], 
indicating the potential limitation for the use of iontophoresis technique. In the current 
study, we determined the effects of acute flavanol intake on MCh-induced cutaneous 
vasodilation in microvasculature by combining intradermal microdialysis. Thus, there is 
the possibility that different size and location of arteries, and measurements may lead to 
different blood flow responses in this study.  
We have previously found that acute flavanol intake improves cutaneous 
microvascular function in response to thermally induced hyperemia in young black 
Americans. However, the acute consumption of FC beverage did not alter the dose-
response curve of MCh-induced cutaneous vasodilation in both races in the current study. 
The reason for this remain unclear; however, there is the possibility that other vasoactive 
substances might be activated and confounded the results on MCh-induced vasodilation. 
Although NO released from endothelial cells acts as a potent vasodilator and is activated 
in response to a variety of stimuli including acetylcholine (Ach), MCh, also results in the 
release of other vasoactive substances including prostaglandins and endothelium-derived 
hyperpolarizing factors (EDHFs) [53, 145]. Thus, there is the possibility that upregulation 
of EDHFs and/or prostaglandins may compensate for decreased NO-dependent 
vasodilation and lead to a maintained endothelial function in young black Americans in the 
current study. Additional studies are needed to explore the effects of EDHFs and/or 
prostaglandins in response to MCh-induced hyperemia in young black Americans.  
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Another possibility is that MCh-induced vasodilation in microvasculature may be 
mediated by different mechanisms, which is distinct from the release of NO. Cyclic 
guanosine monophosphate (cGMP) is synthesized from guanosine triphosphate (GTP) by 
soluble guanylate cyclase (sGC), and NO binds to sGC so vasodilation; thus, cGMP has a 
major role in the regulation of vascular smooth muscle tone [146, 147]. It has shown that 
NO is not involved in the NO-cGMP pathway on ACh-mediated vasodilation [148, 149]. 
In addition, studies with endothelial NO synthase (eNOS) knockout mice have shown that 
ACh-induced vasodilation was only slightly attenuated in isolated first-order gracilis 
muscle arterioles [150, 151]. Notably, a recent study has demonstrated that the inhibition 
of the activation of sGC on responses to NO does not alter ACh-induced vasodilation in 
the pulmonary and systemic vascular beds of the rat [152]. These findings suggest that NO 
has no significant role in ACh-induced vasodilation. We intradermally administrated MCh 
instead of ACh to eliminate the confounding effects of acetlycholinesterase [153]. Thus, 
mechanistic studies are required to confirm this possibility. 
In the current study, we observed that acute consumption of FC did not alter the 
dose-response curve on MCh-induced cutaneous vasodilation in both races. In line with the 
possibility that mentioned above, it is likely that there would be no effects of MCh-induced 
vasodilation in microvasculature even if acute consumption of FC would improve NO-
dependent vasodilation. Taken together, our results suggest that NO does not play a 
significant role in MCh-induced vasodilation so that acute flavanol intake does not show 








A limitation of the current study is that we did not include blood analysis such as 
flavanol metabolites, and nitrate/nitrite to quantify these metabolites in the circulation. 
However, we allowed a 2-hour window in the present study because studies of flavanol 
ingestion have previously demonstrated that plasma concentration of flavanols peak after 
2 hours from the ingestion [92, 119-122]. Furthermore, we believe that the flavanol content 
in FC beverage (792 mg) used in the present study was high enough to elicit the benefits 
of acute flavanol intake in microvascular function when compare to previous studies [26, 
90]. Another limitation of the current study is that we measured MCh-induce vasodilation 
by infusing lactated Ringer’s solution with single intradermal microdialysis membrane. 
This may limits the conclusion that can be drawn from our findings. For future studies, 
using multiple microdialysis sites for NOS inhibitor and/or sGC inhibitor will provide a 




In conclusion, the results of the current study show that the EC50 of dose-response 
curve on MCh-induced vasodilation is not different between young black American and 
white Americans. Furthermore, our finding indicates that the acute consumption of FC does 
not alter the dose-response curve on MCh-induced cutaneous vasodilation in both races. 





6.6 TABLES AND FIGURES 
 
Table 6.1 Product nutrition facts 
 
Per serving Flavanol Non-flavanol 
Calories 224 229 
Fat, g (calculated) 3 0 
Sat fat, g 1.5 0 
Trans fat, g 0 0 
Cholesterol, mg 16.5 18 
Sodium, mg 546 555 
Carbohydrates, g 37.5 39 
Dietary fiber, g 7.5 7.5 
Sugar, g 25.5 30 
Protein, g 21 21 
Vitamin A, IU 15 12 
Vitamin C, mg 3 4.5 
Calcium, mg 643.5 729 
Iron, mg 1.5 0 
Magnesium, mg 169.5 61.5 
Potassium, mg 1170 1014 
Flavanols 1-10, mg 370.8 0.0 
Monomers 97.2 0.0 
Catechin, mg 26.7 0.0 
Epicatechin, mg 70.5 0.0 
2-10 mers 273.6 0.0 
Total flavanols, mg* 729.0 0.0 
 
  * Total flavanols include all flavanols that are greater than 10 polymers. 
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Table 6.2 Subject characteristics  










Age (years) 22 ± 4 22 ± 4 0.89 
Sex (M/F) 4/3 4/3 1.00 
Height (cm) 171 ± 11 169 ± 10 0.82 
Weight (kg) 70 ± 14 69 ± 13 0.92 




Table 6.3 Baseline hemodynamic variables  
NF, beverage without flavanols, FC, flavanol-rich cocoa beverage; HR, heart rate; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. All 
data were collected in the last minute prior to MCh infusion. Baseline hemodynamics were 




White American Black American 
 NF FC NF FC 
HR (beats/min) 63 ± 11 59 ± 8 69 ± 11 65 ± 7 
SBP (mmHg) 114 ± 9 114 ± 6 119 ±10 120 ± 5 
DBP (mmHg) 66 ± 7 67 ± 7 70 ± 10 71 ± 7 




Table 6.4 Baseline cutaneous vascular conductance as a percentage of maximal 
vasodilation in response to local heating (%CVCmax) at ~10 min and ~2 hour after each 
test beverage given in both groups  
NF, beverage without flavanols; FC, flavanol-rich cocoa beverage. At 32 °C, the baseline 
%CVCmax either at the beginning of dietary intervention or 2 hours after beverage given 




  Post ~10 min Post ~120 min 
White American NF 12 ± 2 10 ± 2 
 FC 11 ±2 11 ± 2 
Black American NF 7  ± 2 8 ± 2 
 FC 7  ± 2 8 ± 2 
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Figure 6.1 A summary of absolute maximal cutaneous vascular conductance between the 
highest dose (1M) of MCh on 42 °C heating and 28 mM SNP infusion on 43 °C heating 
in both group  
NF, beverage without flavanols; FC, flavanol-rich cocoa beverage. No racial difference in 
absolute maximal CVC was observed either at maximal dose of Mch between NF and FC 
beverages or at 43°C heating + 28 mM SNP infusion between NF and FC beverages. 
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Figure 6.2 A summary of cutaneous vasodilation in response to incremental doses of methacholine (MCh) in both groups 
Left panel, whit American group; right panel, black American group. NF, beverage without flavanols; FC, flavanol-rich cocoa 
beverage. Log EC50, Hillslope, top, and bottom were not different between NF and FC beverages in both groups (all P > 0.05). 
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Chapter 7: Review of Literature 
This literature review summarizes the relevant research that shows microvascular 
function is impaired in healthy, young black Americans relative to their white counterparts. 
The topics in this review of literature include: 1) cardiovascular disease (CVD) in black 
Americans; 2) microvascular dysfunction as it relates to CVD; 3) the evidence of 
microvascular dysfunction in black Americans; 4) potential mechanisms of attenuated 
microvascular function in black Americans; 5) the benefits of flavanols on cardiovascular 
health; 6) potential mechanisms of improved microvascular function with flavanols; and 





7.1 OVERVIEW OF CARDIOVASCULAR DISEASE IN BLACK AMERICANS 
Black Americans are the largest minority group in the United States. An analysis 
of the U.S. Census in 2010 show that black American population constitutes 13% of the 
total population [154]. In the United States, overall mortality rates rapidly declined during 
this century; however, the mortality rates in black American population are 50% higher 
than white counterparts [155]. In addition, the life expectancy at birth for black American 
men and women is 6.9 and 5.2 years lower than white Americans, respectively [156]. CVD 
is a class of disease, which includes hypertension, heart disease, stroke, and peripheral 
artery disease. Although overall mortality from CVD has continued to decrease over recent 
decades, CVD is still the leading cause of deaths in the United States. It is currently 
estimated that 83 million adults suffer from CVD. In 2008, the estimated annual direct and 
indirect costs associated with the treatment of CVD was already about 300 billion dollars 
[1]. 
Research has shown that black Americans have, traditionally, experienced higher 
rates of mortality and morbidity from CVD than white Americans for every decennial year 
back to 1900 [3, 4, 78]. Black American men and women (44% and 49%, respectively) 
have higher prevalence of CVD than white American men and women (37% and 32%, 
respectively) [79]. Furthermore, CVD prevalence is higher in young black Americans than 
age-matched white Americans (35-44 years) and this racial disparity between young black 
Americans and white Americans may not be explained by clinical and socioeconomic 
factors [24]. Specifically, black American adults have increased CVD risk factors including 
myocardial infarction [123, 124], stroke [125], hypertension and type 2 diabetes [3, 126] 
when compare to white American adults. 
Given the higher mortality and prevalence of CVD in black Americans relative to 
white Americans, black Americans are at greater burden than their white counterpart in the 
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United States even though overall mortality rates and prevalence of CVD have improved 
during recent decades. Therefore, CVD is one of the crucial determinants of racial 
differences in mortality between black Americans and white Americans, and it is 
imperative to investigate underlying mechanisms of increased mortality rates of CVD and 
its risk factors in young black Americans.  
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7.2 PATHOPHYSIOLOGY OF MICROVASCULAR ENDOTHELIAL DYSFUNCTION 
CVD includes a variety of diseases in the heart and vasculature [1]. It is well 
established that atherosclerosis is a common pathological stage for the development of 
CVD, which is initiated by the impairment of the endothelium in vasculature [157-159]. 
The microvasculature consists of small arterioles, capillaries, and venules, and its main 
functions include the delivery of oxygen and nutrients to the cell, elimination of carbon 
dioxide and other metabolic byproducts from the cell, controlling blood pressure, and 
regulation of body temperature. A large proportion of the endothelium lies on the internal 
surface of microvessels and produces vasoactive molecules to keep vascular tone and   
homeostasis [77, 160].  
The endothelium is a single intimal layer of arterial walls, and it was initially 
considered a physical barrier to protect and separate blood and its contents from underlying 
tissue in the past. However, the endothelium is now believed to serve as not only a physical 
barrier but also the place where endothelial cells maintain vascular homeostasis by the 
interplay with various vasoactive molecules [161]. The major functions of the endothelium 
are to regulate vascular homeostasis and maintain the balance between: 1) vasodilation vs. 
vasoconstriction; 2) inhibition vs. stimulation of smooth muscle cell proliferation & 
leukocyte migration; and 3) thrombogenesis vs. fibrinolysis. Therefore, endothelial 
dysfunction can interrupt one or all of these functions, resulting in the development of CVD 
[129]. 
NO is a potent vasodilator formed by the reaction of NO synthase (NOS), which 
divides the substrate L-arginine into NO and L-citrulline. Three constitutive isoforms of 
NOS can produce NO, including endothelial NOS (eNOS), neuronal NOS, and inducible 
NOS [129, 162]. Several cofactors are also related to NO production, including 
tetrahydrobiopterin (BH4), nicotinamide adenine dinucleotide phosphate (NADPH) 
 91 
oxidase, heme, flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN) 
[163, 164].  
In the endothelium, once NO is produced and released from the endothelial cells, it 
diffuses to the vascular smooth muscle cells using its highly lipophilic and diffusible 
properties. At the smooth muscle cells NO binds to and thus activates guanylate cyclase, 
which triggers a cascade of intracellular events ultimately resulting in vasodilation. 
Signaling molecules, such as adenosine, bradykinin, endothelial growth factor, and 
serotonin, also participate in cell signaling which contributes to endothelium-dependent 
vasodilation [165, 166]. In addition, NO-independent vasodilatory substances exist and 
responsible for vascular homeostasis. Kellogg et al. (2005) administered ketorolac, an 
inhibitor of prostaglandin production, directly into the interstitial space within local areas 
of the skin by using intradermal microdialysis. They found that prostaglandins are a potent 
vasodilator and released from endothelial cells [145]. Several recent investigations also 
suggest that endothelium-derived hyperpolarization factors probably affect NO production 
via an independent pathway [167, 168]. 
The endothelium releases not only vasodilator substances such as NO and 
prostaglandins, but also secretes vasoconstrictor substances. For example, Kinlay et al. 
(2001) reported that endothelin-1 accounts for 39% of the coronary tone in normal arteries 
and acts as a vasoconstrictor in atherosclerotic coronary arteries [169]. Vasoconstrictor 
prostanoids generated at the endothelium and the conversion of angiotensin I to angiotensin 
II at the surface of the endothelium also modulate vascular tone, acting as vasoconstrictors 
[170].  
Therefore, vascular tone is ultimately the function of a coordinated balance between 
endothelium-derived vasoconstrictors and vasodilators, and it is critical to prevent 
endothelial dysfunction and to keep overall vascular health. In a normal condition, the 
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endothelial cells regulate vascular homeostasis by balancing between vasoconstriction and 
vasodilation and thereby protecting the initiation of the atherosclerotic process. However, 
acute and/or chronic disruptions in the balance between vasoconstriction and vasodilation 




7.3 MICROVASCULAR DYSFUNCTION IN BLACK AMERICANS 
As stated above, black Americans have higher rates of mortality and morbidity from 
CVD including stroke, coronary artery disease, hypertension, and metabolic syndrome 
compared to white Americans [3, 4]. The exact mechanisms which increases the risk of 
cardiovascular diseases in black Americans are complicated and multifactorial; however, 
recent studies show that endothelial dysfunction, related to decreased NO bioavailability 
in this population, is a major contributor for the increased risk of cardiovascular diseases 
[23, 27]. 
Post-occlusive reactive or thermal hyperemia on the blood vessels has been widely 
used as a measure of endothelial function because an increased shear stress on the 
endothelial cells elicit an increase in NO production and vasodilation [165, 171]. For this 
reason, many investigators have used venous occlusion plethysmography to test 
endothelial function in macro- and micro-vasculatures. Previous studies have reported that 
the vascular dilatory responses to hyperemia in resistance vessels are attenuated in young 
black Americans relative to young white Americans. For example, Bassett et al. 
investigated vasodilatory capacity in normotensive young black and white Americans. 
They found that vasodilatory capacity of the forearm resistance vessels was lower in young 
black Americans men when compared to young white American men [28].  
In addition, forearm vasodilatory response to isoproterenol (β-adrenergic agonist) 
was blunted in normotensive young black American men relative to white American men 
[172]. NO mediated forearm blood flow responses to the administration of methacholine 
and sodium nitroprusside (SNP) were attenuated in healthy young black American men 
compared with white American men [30]. Similarly, Campia et al. noted that black 
Americans have blunted endothelium-dependent and -independent vasodilation of the 
brachial artery indexed by flow-mediated dilation and nitroglycerin-mediated dilation 
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relative to white Americans [127]. Therefore, these results might indicate early onset of 
endothelial dysfunction in healthy young black Americans prior to any overt signs of risk 
compared with young white Americans.  
Although most studies on endothelial function in human vessels have focused on 
macrovessels by using plethysmography, there is an increased interest in how endothelial 
function contributes to alterations in the microcirculation. Researchers recently have 
recognized that impairment of microvascular function is involved in cardiovascular and 
metabolic diseases. Racial differences of macrovascular function have been investigated; 
however, the role of racial differences in microvascular function are not fully understood. 





7.4 POTENTIAL MECHANISMS OF MICROVASCULAR DYSFUNCTION 
Structurally, the active eNOS enzyme is a dimer. On the C-terminal, a reductase 
domain binds NADPH, FMN, and FAD. On the other side, the N-terminal oxygenase 
domain contains a heme group and the binding sites for BH4, oxygen, and L-arginine. The 
eNOS dimer is normally inactivated and associated with caveolae which are a type of lipid 
raft in the endothelial cell membrane. Once intracellular Ca2+ concentration increases with 
stimulation such as shear stress, calmodulin is activated and then released from caveolin-1 
and, in turn, binds to eNOS and results in the production of NO [173, 174]. When the tight 
regulation of eNOS is disturbed, the eNOS dimer is uncoupled and the oxygenase domain 
begin to generate superoxide anion (O2
−) instead of NO thus decreased NO bioavailability. 
The eNOS uncoupling may arise from: 1) upregulation of NADPH oxidase and/or xanthine 
oxidase (XO); 2) BH4 deficiency; 3) A limited availability of L-arginine; and 4) 
upregulation of asymmetric dimethylarginine (ADMA). 
Upregulation of NADPH oxidase and XO. NADPH oxidase is an important source 
of reactive oxygen species (ROS) [175]. NADPH oxidase on the endothelial cell membrane 
transfers electrons from NADP to molecular oxygen and produce O2
−. XO is another 
important source of ROS in the vasculature. This enzyme donates electrons to produce O2
− 
and hydrogen peroxide (H2O2). It has been found that XO inhibition reduces O2
− production 
and improves NO-dependent vasodilation [176]. Taken together, it has been suggested that 
the upregulation of NADPH oxidase and/or XO are related to eNOS uncoupling. 
BH4 deficiency. BH4 is the essential cofactor for the generation of NO by eNOS. 
The lack of BH4 in the endothelial cells can cause eNOS uncoupling [177]. For example, 
the infusion of BH4 into the human arterial circulation improves endothelium-dependent 
vasodilation in smokers [178], suggesting that a decrease in BH4 concentration may cause 
eNOS uncoupling [68, 179]. In addition, one possible mechanism of eNOS uncoupling 
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related to BH4 has suggested that the formation of peroxynitrite (ONOO
–) due to elevated 
oxidation may oxidize BH4 [67]. Excessively produced O2
− by NADPH oxidase and/or XO 
can bind with NO and form ONOO–. The oxidization of BH4 by ONOO
– is converted to 
BH3 or BH2 which are inactive forms of BH4, leading to eNOS uncoupling [68-70]. 
Furthermore, it has been assumed that ONOO– might oxidize the zinc-thiolate cluster of 
eNOS and destabilize eNOS dimer so eNOS is uncoupled [71]. Therefore, oxidative stress 
may decrease BH4 availability and result in increasing eNOS uncoupling. 
Limited availability of L-arginine. eNOS produces endothelium-dependent NO 
from L-arginine. The availability of L-arginine may be one contributor to eNOS 
uncoupling. Studies have shown that a low concentration of L-arginine can limit the 
production of NO in both animals and human cells [32, 71]. This data suggests that a 
decrease in the amount of L-arginine may reduce NO bioavailability due to eNOS 
uncoupling. L-arginine in human cells not only binds with eNOS, but also with arginase 
[34, 35, 38-40]. Therefore, the concentration of arginase can also cause eNOS uncoupling 
due to competition for the share the substrate L-arginine. 
Upregulation of ADMA. ADMA found in blood plasma is also closely related to 
uncoupled eNOS. ADMA, an endogenous competitive antagonist of eNOS, interferes with 
L-arginine in the production of NO [180, 181]. Vallance et al. (1992) initially assumed the 
hypothesis that ADMA was related to NOS. They administrated L-NG-monomethyl-L-
arginine (L-NMMA) and found that the high concentrations of plasma ADMA was 
negatively correlated to NOS activity in chronic renal failure patients, suggesting that 
ADMA is one of the important endogenous NO inhibitor [182]. Data from other studies 
have supported the idea that ADMA may play a role in the inhibition of eNOS [183, 184]. 
In addition, increased oxidative stress might promote the expression of ADMA by 
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inactivating dimethylarginine dimethylaminohydrolase, which also contributes to eNOS 
uncoupling [185].  
Taken together, endothelial function might be related to NO bioavailability, which 
is closely dependent on eNOS coupling. The eNOS may be regulated via NADPH and XO, 
BH4, L-arginine, and arginase. Therefore, endothelial dysfunction due to a decrease in NO 
bioavailability might occur when any of these factors are disrupted.  
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7.5 THE BENEFITS OF FLAVANOLS ON CARDIOVASCULAR HEALTH 
Overtime, there has been an emerging interest for flavonoids due to their potential 
beneficial effects on cardiovascular health. Epidemiological studies have explored whether 
the dietary intake of flavonoids is related to CVD risk; however, the data from many 
epidemiological studies have shown mixed results [84, 186-190]. 
The effects of flavonoids on cardiovascular health. Over 4,000 flavonoid have been 
classified based on their chemical structure. The basic flavonoid skeleton consists of 15 
carbon atoms with two aromatic rings (Ring A and Ring B) that are connected by 3-ring 
carbon backbone (Ring C) [191, 192]. They are usually subdivided into several subgroups 
according to which functional groups are attached to the ‘C-ring’ of this 3-ring carbon 
backbone [131]. The main subgroups of flavonoids include flavanols (cocoa, tea, fruits, 
and wine), flavanones (juices), flavonols (broccoli, onion, tea, and tomato), anthocyanidins 
(berries and wine), flavones (herbs), and isoflavones (soybean). It has estimated that 
average daily total flavonoid intake of U.S. adults is 189.7 mg/day mainly from flavanols 
(83.5%), flavanones (7.6%), flavonols (6.8%), anthocyanidins (1.6%), flavones (0.8%), 
and isoflavones (0.6%) [86]. Recently, flavanols, a subgroup of flavonoids, have gained 
increasing attention due to their reported benefits on cardiovascular health. Flavanols are 
abundant in cocoa-containing products, green tea, red wine, and soy products [87]. The 
estimated mean flavanol intake of U.S. adult is in the range of 50-100 mg/day [88]. 
Flavonoids are digested mainly in the small intestine and the liver. Flavonoids metabolites, 
which are chemically and structurally distinct from flavonoids, reach the target tissues 
through the circulation [131, 132] and each subgroup of flavonoids leads to different 
physiological effects on cardiovascular health [133, 134]. 
It have been indicated that flavonoids are inversely associated with CVD. For 
example, Hertog et al. (1993) reported that individuals who consumed higher amount of 
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flavonoids in their diet had a 68% lower cardiovascular risk when compared with 
individuals who consumed less flavonoids in their diet [193]. Sesso et al. (1999) also 
observed a significant reduction of cardiovascular risk in individuals who drank more than 
one cup of flavonoids containing tea per day than individuals who did not drink flavonoids 
containing beverage [194]. Interestingly, it has been suggested that flavonoid intake in the 
form of tea might have benefits for individuals with established CVD. In this prospective 
cohort study, cardiovascular risk reduced in individuals who consumed moderate and 
heavy tea beverage (31% and 39% respectively) among 1,900 individuals with acute 
myocardial infarction [195]. 
On the contrary, other studies have demonstrated that there is no relationship 
between flavonoid intake and cardiovascular risk. For example, the results from the 
Scottish Heart Healthy Study indicates there is no relationship between coffee or tea 
consumption and coronary heart disease [196]. Similarly, Rimm et al. (1996) found that 
flavonoid intake did not significantly associate with coronary heart disease [197]. In 
addition, a 14-year follow-up study demonstrated that tea consumption to which milk was 
added was not related to ischemic heart disease in a cohort of 1,900 Welsh men [198]. 
These complicated results from epidemiological studies, regarding the effects of flavonoid 
on cardiovascular health, might be related to subtle differences in the chemical structures 
of several subgroups in flavonoids [132]. Therefore, it might be an important implication 
for dietary recommendations if the positive vascular effects of flavonoids are partly due to 
a limited number of flavonoid subgroups.  
The benefits of flavanol-rich cocoa on cardiovascular health. Flavanols are 
distinguished from other subgroups of flavonoids by the presence of a hydroxyl group at 
position 3 of ring C [87]. Flavanols are mainly present in a mixture of monomeric (−) 
epicatechin and (+) catechin and oligomeric and polymeric proanthocyanidin flavanols 
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[199]. Furthermore, a small amount of gallocatechin and epigallocatechin have also been 
indentified [200]. Cocoa, a well-known source of flavanols, has especially received a great 
deal of attention because of their independent beneficial effects on cardiovascular health. 
The observation of Kuna Indians of Panama by Hollenberg et al. initiated this attention. 
They have conducted a series of studies and found that individuals living in the island of 
San Blas, which is located just off the coast of Panama, have a significantly lower incidence 
of CVD when compared to individuals who moved to the mainland from San Blas. These 
investigators have reported the possibility that the difference in incidence of CVD between 
these Kuna Indians is dependent on the consumption of cocoa containing beverages that 
are mostly consumed by Kuna Indians living on the island. [201-206]. Numerous 
epidemiological and prospective follow-up studies have supported this hypothesis, which 
confirms an inverse correlation between the consumption of flavanol-rich cocoa and 
cardiovascular risk [16, 18, 207, 208].  
The exact underlying mechanisms involved in reducing CVD risk factors with the 
supplementation of flavanol-rich cocoa are not been fully understood; however, recent 
evidence suggest that flavanol intake might modulate cardiovascular risk via the 
improvement of endothelial function, the inhibition of oxidative low-density lipoprotein 
production, and/or the decrease in blood pressure. A number of meta-analyses has shown 
that cocoa intake lowers both systolic and diastolic blood pressure which leads to a 
decrease in cardiovascular risk, presumably due to an improvement of endothelial function 
with an increased NO bioavailability [89, 209, 210]. In support of this hypothesis, it has 
been reported that acute and long-term supplementation of flavanols improve endothelial 
function in healthy individuals [91, 96, 97] and more effectively than in individuals with 
endothelial dysfunction [90, 92]. 
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Although it is not conclusively explored which specific active compounds of cocoa 
are responsible for the improvement of CVD risks, studies have suggested that epicatechin 
and its metabolites are major contributors. [90, 92, 211]. In addition, it has been proven 
that the acute effects of epicatechin on vasculature are similar between the consumption of 
chemically isolated pure epicatechin from cocoa and the consumption of epicatechin from 
flavanol-rich cocoa. [121], indicating that the specific flavanols in cocoa are capable for 
improving vascular health. 
Taken together, it is still controversial if the consumption of flavanol-rich cocoa 
could provide beneficial effects on CVD and its related risk factors; however, a majority 
of studies suggest that the specific subgroups of flavanols have a significant role in 
improving vascular function and prevent CVD. Therefore, additional investigation will 




7.6 POTENTIAL MECHANISMS OF IMPROVED VASCULAR HEALTH WITH FLAVANOLS 
The underlying mechanisms by which flavanol intake improves endothelial 
function in young black Americans has not been fully explored. However, given that 
endothelial dysfunction due partly to decrease in NO bioavailability is commonly observed 
in black Americans [23, 66, 101] and that flavanols are exert positive effects on endothelial 
function in part by an increase in NO bioavailability [121, 212], it is plausible to suggest 
that the flavanol intake may improve endothelial function in young black Americans, via 
an improvement in NO mediated vasodilation. Hypothesized mechanistic pathways include 
an increase in antioxidant capacity, an increase in eNOS expression/activity, a decrease in 
arginase activity, and/or an increased in L-arginine availability. 
Flavanols exert their beneficial actions in part through their antioxidant like 
properties via the neutralization of ROS and the inhibition of ONOO– production. The 
aromatic rings (Ring A and Ring B) delocalize electrons and scavenge ROS. These 
aromatic rings directly neutralize free radicals including O2
− and chelate metals such as 
Fe2+ and Cu+, and thus decrease in ROS [18]. It has been reported that consumption of 
flavanol-rich cocoa improves serum antioxidant capacity, indicating that flavanols preserve 
endothelial function from oxidative stress and endogenous ROS [213], It has been 
demonstrated that reduced NO bioavailability in young black Americans (22 years) is 
related to the upregulation of O2
− (65), which leads to a reduction in NO bioavailability as 
they react with NO to form ONOO– (68, 69). Similarly, Manson et al. (2005) have shown 
that NO production is improved by a NADPH oxidase inhibitor in young black Americans 
(102). Additionally, studies have demonstrated that epicatechins reduce the production of 
free radicals including O2− through of NADPH oxidase, which in turn, improves NO 
bioavailability (103, 104). These findings suggest flavanols may affectively reduce 
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oxidative stress and endogenous ROS and improve NO bioavailability in young black 
Americans. 
Beyond antioxidant capacity of flavanol-rich cococa, another potential mechanism 
of improved NO bioavailability associated with flavanol consumption in young black 
Americans is an increase in eNOS coupling by indirect pathways, including upregulation 
of eNOS activity, inhibition of arginase activity, and/or improvement of L-arginine 
availability in the endothelial cells. In vitro studies, endothelial cells incubated with 
flavonoid-rich red wine upregulated eNOS mRNA and protein expression, producing more 
bioactive NO (up to 3 times) when compared to control cells with no treatment (105). Plant 
extracts rich in flavonoids also upregulated eNOS activity in cultured endothelial cells 
(106, 107) and rat aorta (108). In terms of arginase activity, it has been suggested that 
flavanol-rich cocoa reduces arginase activity in human endothelial cells, leading to increase 
in local concentrations of the substrate, L-arginine. A series of studies by Schnorr et al. 
demonstrated that arginase II mRNA expression in human umbilical vein endothelial cells 
(HUVECs) is reduced in two hours when they incubated with epicatechines. They also 
observed that arginase II activity was reduced in rats with high flavanol intake for 28 days 
and in human erythrocytes with high flavanol intake for 24 hours, respectively, indicating 
that flavanol-rich cocoa may reduce arginase activity in human endothelial cells and leads 
to increase in local concentrations of the substrate, L-arginine. [109]. These findings 
suggest the possibility that flavanols may improve eNOS coupling by indirect pathways, 
including upregulation of eNOS activity, inhibition of arginase activity, and/or 
improvement of L-arginine availability in the endothelial cells.  
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7.7 LOCAL HEATING OF SKIN TO EVALUATE MICROVASCULAR FUNCTION 
In the human cutaneous vasculature, both neurogenic reflexes and local control 
factors regulate skin blood flow (SkBF). The skin is comprised of glabrous and non-
glabrous (hairy) portions and non-glabrous skin is predominantly present on most of the 
body surface [214]. In the non-glabrous skin, a change in skin temperature elicits two 
sympathetic pathways that are responsible for the control of the cutaneous vasoreflexes: an 
adrenergic vasoconstriction system and an active vasodilation system. For example, the 
direct local cooling of the skin reduces SkBF mediated by reflex activation of the 
sympathetic nervous system and requires norepinephrine release from vasoconstrictor 
nerve terminals. On the other hand, local heating of skin to 42°C causes maximal cutaneous 
vasodilation [113, 215] independent of changes in core temperature and activation of 
thermoregulatory reflexes [216]. 
Local heating of skin elicits cutaneous blood flow reactivity in two distinct phases 
that is marked by an initial peak and is followed by a plateau [43, 62, 112]. The local axon 
reflex mechanism primarily mediated by sensory nerves which induce a rapid initial peak 
in SkBF the first 10 min which is minimally dependent on NO. This is followed by a plateau 
in SkBF after about 20~30 min that is approximately 50–75 % dependent on NO [62, 77, 
113, 166] and involves several pathways including transient receptor potential vanilloid 
type-1 (TRPV1) channels [114], adenosine receptors [115], and reactive oxygen species 
[116], while the remaining 30% of vasodilation on the plateau depends on endothelium-
derived hyperpolarizing factors (EDHFs) that stimulate calcium-activated potassium 
channels on endothelial and smooth muscle cells [110]. 
It has been suggested that the human cutaneous circulation serves as a surrogate 
vascular bed for the assessment of global vascular health in vivo. For example, impaired 
cutaneous microvascular reactivity is observed before any clinical signs of microvascular 
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dysfunction during the early stages of diseases [42], suggesting the correlation between 
skin vascular reactivity and a systemic microvascular dysfunction. For this reason, SkBF 
response to local heating has been widely used as a means to examine microvascular 
dysfunction because of its ease of accessibility and non-invasive characteristics [44-46].  
Additionally, the combination of laser-Doppler flowmetry (LDF) and intradermal 
microdialysis has been successfully used in skin reactivity tests to measure microvascular 
function and determine the underlying mechanisms of microvascular dysfunction in both 
healthy and diseased populations. Vasoactive substances delivered via intradermal 
microdialysis allow the investigation of how cutaneous vascular reactivity is affected in 
those with a higher risk of CVD that is related to endothelial dysfunction. For example, 
endothelial dysfunction is closely associated with NO bioavailability, which has been 
shown via the combination of LDF and intradermal microdialysis in populations with 
elevated CVD risk factors including smoking [47], hypercholesterolemia, and essential 
hypertension [49]. Therefore, the combination of a typical local heating protocol and 
microdialysis might provide better knowledge to understand the underlying mechanisms 




Chapter 8: Conclusion 
8.1 SUMMARY 
The overall goal of this dissertation was to investigate potential mechanisms of 
microvascular dysfunction in young black Americans and to test the hypothesis that 
microvascular function might be improved by dietary flavanol supplementation in young 
black Americans. In a series of studies within this dissertation we combined laser-Doppler 
flowmetry and microdialysis technique to measure microvascular function and determine 
the underlying mechanisms of microvascular dysfunction.  
In study 1, we explored the potential mechanisms of impaired cutaneous 
microvascular function in young black Americans. We hypothesized that microvascular 
function in response to local heating of skin would be attenuated in young black Americans 
relative to age-matched white Americans due largely to the lack of nitric oxide (NO) 
bioavailability. We also hypothesized that such attenuated cutaneous microvascular 
function in young black Americans would be improved with an intradermal infusion of L-
arginine and arginase inhibitors, respectively. Our results suggest that limited NO 
bioavailability due partly to a relative deficit of L-arginine in the endothelium is one of the 
mechanisms by which microvascular dysfunction occurs in young black Americans when 
compared to age-matched white Americans. This conclusion is in accordance with previous 
findings that a low concentration of L-arginine could limit the production of NO in both 
animals [32] and human cells [33] , indicating that a decrease in the amount of L-arginine 
may reduce NO bioavailability. Furthermore, our results suggest that increased competition 
from arginase is not a likely mechanism of microvascular dysfunction in young black 
Americans as we did not observe any differences in %CVCmax, an index of microvascular 
function, between the lactated Ringer’s infused and arginase-inhibited microdialyis sites in 
both racial groups. This conclusion is consistent with those of Holowatz et al. (2006) who 
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previously reported that intradermal administration of arginase inhibitors did not alter 
cutaneous vasodilation in young subjects [34], indicating that upregulation of arginase 
activity is not a limiting factor of NO bioavailability in young individuals. Taken together, 
considering attenuated microvascular function due partly to limited NO bioavailability in 
young black Americans and the observed restoration of cutaneous microvascular function 
with the administration of L-arginine, a relative deficit of L-arginine in the endothelium is 
one of the mechanisms by which microvascular dysfunction occurs in young black 
Americans. 
Study 2 was designed to explore the effects of acute flavanol intake on thermally 
induced vasodilation in young black Americans. We hypothesized that acute flavanol 
intake would improve microvascular function in response to local heating of skin in young 
black Americans relative to young white Americans. We further hypothesized that such 
improvement with flavanol intake would be related to an increase in NO bioavailability. 
Our results suggest that acute consumption of flavanol-rich cocoa improved NO-dependent 
microvascular endothelial function in young black Americans relative to age-matched 
white Americans. The underlying mechanisms by which flavanols improve NO 
bioavailability in young black Americans are needed further mechanistic investigation to 
confirm our results; however, decreased oxidative stress and/or increased endothelial NO 
synthase (eNOS) coupling associated with flavanol intake have been proposed as major 
contributors [103, 104]. Taken together, our results suggest that acute flavanol intake may 
improve NO bioavailability and microvascsular function in young black Americans 
through reducing oxidative stress level and/or increasing eNOS coupling. 
Study 3 was designed to explore the effects of acute flavanol intake in methacholine 
(MCh)-induced vasodilation in young black Americans. We hypothesized that young black 
Americans would require a higher dose of Mch to achieve 50% of maximal dilation (EC50) 
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when compare to age-match white Americans. We further hypothesized that acute flavanol 
intake would produce a leftward shift in the dose-response curve of MCh-induced 
cutaneous vasodilation in young black Americans, while there would be no effects of acute 
flavanol intake in young white Americans. Contrary to our hypotheses, we found that the 
EC50 of dose-response curve on MCh-induced cutaneous vasodilation was similar between 
racial groups. Furthermore, the acute consumption of flavanol-rich cocoa did not alter the 
dose-response curve on MCh-induced cutaneous vasodilation in both races. This study was 
not mechanistic by design so we are not able to explain the exact mechanisms of our 
findings. However, it is likely that MCh-induced hyperemia may activate other vasoactive 
substances including prostaglandins and endothelium-derived hyperpolarizing factors 
(EDHFs), which compensate for decreased NO-dependent vasodilation [53, 145] and 
contribute to maintain microvascular endothelial function in young black Americans. It is 
also plausible that MCh-induce vasodilation in microvasculature may be mediated by 
different mechanisms, which are distinct from the release of NO (134, 135). In line with 
this possibility, it is likely that there would be no effects of MCh-induced vasodilation in 
microvasculature even if acute flavanol intake would improve NO-dependent vasodilation. 
Taken together, our results suggest that NO does not play a significant role in MCh-induced 
vasodilation so that acute flavanol intake does not show any changes in NO-dependent 
vasodilation in young black Americans; however, additional mechanistic studies in larger 
group are required to confirm our findings. 
 
8.2 PERSPECTIVES 
Despite remarkable evidence that endothelial dysfunction is a major contributor to 
develop cardiovascular disease (CVD) and its risk in black Americans, the exact 
mechanisms of endothelial dysfunction in microvasculature have not fully elucidated. Our 
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findings that limited availability of L-arginine in the endothelium is a potential mechanism 
of attenuated NO-dependent microvascular function in young black Americans, at least in 
part, provide clinical relevance of the heightened risk of CVD in this population. Similarly, 
the benefits of flavanol-rich cocoa in vascular health have been explored at length, while 
there is uncertainty whether acute consumption of flavanol-rich cocoa improve 
microvascular function in young black Americans. Our findings that acute consumption of 
flavanol-rich cocoa improved NO-dependent microvascular function is young black 
Americans provide a novel potential therapeutic target to delay onset of microvascular 
endothelial dysfunction and prevent the development of CVD in this population. Future 
mechanistic studies are needed to determine the underlying mechanisms of improved NO-
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